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Maternal cardiac metabolism during pregnancy 
 
Abstract 
 
Pregnancy profoundly alters maternal physiology in response to the demands of the fetus. 
Cardiac output increases in response to an increase in heart rate and stroke volume. Insulin 
resistance and fetal preference for glucose switches maternal usage to that of predominantly fat 
consumption. Previous studies have shown that the heart adopts these adaptions, but much still 
remains unanswered. We sought to fill this gap by exploring cardiac substrate utilization and 
metabolic regulation during late pregnancy in mice.  
We found that by late gestation, serum triglycerides are elevated and serum glucose is 
unchanged. Furthermore, real-time bioluminescence imaging of late pregnant mouse hearts 
showed an increase in fatty acid uptake. But greater supply and uptake may not always equal 
greater oxidation. Using 13C-tracer analysis of Langendorff perfused ex vivo hearts, we observed 
~30-50% less glucose usage in late pregnant mouse hearts. Fatty acid utilization, on the other 
hand, is increased.    
The mechanisms regulating substrate switch in late pregnant mouse hearts have not been 
extensively studied. We determined that mitochondrial DNA copy number, morphology, 
expression of oxidative phosphorylation (OXPHOS) proteins, and respiratory capacity remain 
unaltered in late pregnancy. Furthermore, substrate transporter (GLUT4 and CD36) expression 
and localization are unchanged. Interestingly, pyruvate dehydrogenase kinase 4 (PDK4) is 
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induced in late pregnant mouse hearts. PDK4 is a crucial regulatory enzyme that can decrease 
glycolysis by phosphorylation of pyruvate dehydrogenase (PDH). Consistent with this, we 
observed an increase in phospho-PDH in late pregnancy. Treatment of neonatal rat ventricular 
myocytes (NRVMs) with progesterone, a pregnancy hormone, induced PDK4 expression. 
Mifepristone, an antagonist of the progesterone receptor (PR), mitigated PDK4 induction, 
suggesting that PR-mediated pathway is responsible for this upregulation. Taken together, these 
studies indicate that the substrate switch in late pregnant mouse hearts resulting in decreased 
glucose oxidation and increased fatty acid utilization is likely by inhibition of PDH via PDK4 
upregulation.  Dysregulation of this switch could have implications for cardiac diseases during 
pregnancy.  
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Chapter 1: Introduction 
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Systemic maternal metabolism during pregnancy 
The maternal adaptations that occur during pregnancy are complex, coordinated, and 
dynamic. Profound systemic metabolic changes occur, all to facilitate the growth and well-being 
of the fetus and placing the needs of the mother second. During early pregnancy, where growth is 
relatively slow (and placental formation and development of embryonic and gross fetal 
anatomical features take precedence), maternal metabolism is characterized as anabolic, in which 
increases in fat storage and insulin sensitivity promote the hoarding of nutrients. This is all in 
preparation for late pregnancy, a time when both fetal growth and maternal output are at its 
highest and a time of the greatest energetic needs, which is accordingly deemed a catabolic state 
(Figure 1.1). Serum changes in many of the macronutrients throughout gestation are presented in  
Table 1. Concurrently, the hormonal milieu is also dynamically altered during pregnancy (Figure 
1.2). Human chorionic gonadotropin (hCG) is secreted early on and acts to signal the initial 
adaptations of pregnancy, including maintenance of the early secretion of progesterone, which 
along with estrogen, prolactin, and cortisol, acts to transform the maternal environment for fetal 
development. The changes in hormone levels are thus synchronized to maternal metabolic 
alterations, all working in concert to promote the prosperity of the fetus.  
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Figure 1.1: Metabolic changes during late pregnancy. Late pregnancy is marked by 
maternal catabolism that serves to support the dramatic anabolic growth of the foetus. The 
liver uses glycerol and (less so) amino acids to make glucose for the foetus and consumes fats, 
generating in the process ketones that are usable by the brain, muscle, and foetus. Adipose 
tissue releases fatty acids for consumption by both the liver and muscle. The foetus uses 
amino acids, fats, and roughly half of incoming glucose for anabolic growth, while largely 
relying on the other half of glucose for energetic needs. 
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Glucose metabolism 
Alterations in glucose metabolism during pregnancy have been well characterized (King, 
2000; Lain and Catalano, 2007). The main energetic substrates for the developing fetus are 
approximately 80% glucose and 20% amino acids, and maternal metabolism acquiesces to those 
needs by deferring its own glucose usage (Battaglia and Meschia, 1978). Fasting glucose levels  
begins to decline in the second trimester, and ultimately decreases by 10% by late pregnancy 
(Lind, 1979). Interestingly, hepatic glucose production increases by 16-30% (via 
gluconeogenesis and glycogenolysis), and an increase in fasting insulin levels is observed as well  
Figure 1.2: Hormonal milieu of pregnancy. Throughout pregnancy, hormones are secreted 
both early and late, and have been found to be responsible for many of the maternal 
adaptations of pregnancy. Human chorionic gonadotropin (hCG) is secreted early on and acts 
to signal the initial adaptations of pregnancy. Progesterone, estrogen, and prolactin all steadily 
increased throughout pregnancy and peak by around late pregnancy.  
5 
 
(Butte, 2000). Insulin sensitivity is also profoundly affected, as measured by euglycemic-
hyperinsulinemic clamps (Buchanan et al., 1990; Catalano et al., 1991; Ryan et al., 1985). In 
early pregnancy, an approximately 10% decrease in sensitivity is observed, compared to non-
pregnant. However, by late pregnancy, various studies have found decreases from 33-78%, a 
change so drastic that late pregnancy is comparable to a type 2 diabetic state. Furthermore, this 
may be an underestimate as the fetus utilizes insulin-independent glucose consumption methods. 
Serum glucagon, on the other hand, is much less affected, and minimal to no changes have been 
found in late pregnancy.  
The mechanisms of insulin resistance in late pregnancy are unknown, although many 
studies have pointed to hormones as being responsible. Many hormones, including human 
placental lactogen (HPL), progesterone, prolactin, and cortisol can affect insulin sensitivity 
(Newbern and Freemark, 2011; Ryan and Enns, 1988; Sutter-Dub, 1979). One placental 
cytokine, however, has been more strongly correlated to decreased sensitivity than others and 
was the only predictor among all the hormones to be a strong indicator of insulin responsiveness 
– tumor necrosis factor-α (TNF-α) (Kirwan et al., 2002). In vitro studies have shown that TNF-α 
affects insulin signaling pathways by increased serine phosphorylation of insulin receptor 
substrate-1 (IRS-1), therefore preventing interactions with the insulin receptor (Hotamisligil et 
al., 1996; Rui et al., 2001).  
Insulin secretion increases steadily during pregnancy, by approximately 50% in mid-
pregnancy, before peaking in the third trimester (Bleicher et al., 1964). This increase is not in 
response to insulin resistance, as that occurs before the onset of insulin resistance, but is in 
parallel with the establishment of the placenta and production of hormones during pregnancy; 
however, it is not clear if hormones contribute to this phenotype. Pancreatic β-cells are also 
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affected and become hypertrophic and hyperplastic in both animal and human pregnancies (Van 
Assche et al., 1978). Furthermore, in the limited studies available, there is evidence of greater 
insulin secretion and synthesis on the cellular level. Lactogenic hormones and activation of the 
serotonin synthesis pathway in β-cells are responsible for this expansion in order to meet insulin 
needs during pregnancy (Brelje et al., 1994; Huang et al., 2009; Kim et al., 2010).   
Thus, as glucose is the primary substrate source for the fetus, maternal glucose 
metabolism is altered in many ways, including adapting insulin secretion and sensitivity, so as to 
facilitate fetal needs.  
 
Lipid Metabolism  
Maternal usage of lipids as the primary energy source is the result of the anabolic to 
catabolic transition that occurs by late pregnancy and facilitates the fetal usage of amino acids 
and glucose. Maternal adipose stores increases by as much as 3.5 kg on average by late 
pregnancy, second only to increases in total body weight (Lain and Catalano, 2007). Insulin 
resistance dictates lipolysis in adipose tissue. Free fatty acids (FFA) and glycerol that are 
liberated from adipose during pregnancy go to the liver, where they are then re-packaged into 
VLDLs and released back to the circulation. Thus, a concurrent increase in serum lipids is 
observed (potentially a result of estrogen effects on the liver), to establish a hyperlipidemic state 
of 2-4 fold increases in triglycerides, a 25-50% increase of total cholesterol and a 50% increase 
of LDL (Mshelia et al., 2010). The environment that is created is relatively atherogenic and can 
increase the risk of endothelial damage during pregnancy. Glycerol is also the primary substrate 
for gluconeogenesis, allowing amino acids to be saved as a substrate source for the fetus 
(Zorzano and Herrera, 1986). In addition to the increase in gluconeogenesis in the liver, 
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ketogenesis is also observed, as another method to decrease maternal glucose usage (Remesy and 
Demigne, 1986). Ketone bodies can also cross the placental barrier to become a source of energy 
for the fetus (Herrera, 2002; Seccombe et al., 1977).  
The fetus is also capable of taking up fatty acids. Maternal lipoproteins cannot 
themselves cross the placenta, and so they become a “floating energy deposit” (Ghio et al., 
2011). Placental lipoprotein lipases (LPL) can interact with lipoproteins, as can fatty acid 
binding proteins, to take up the fat (Herrera et al., 2006). The imported lipids are then used for 
membrane support, triglyceride synthesis, or for the development of adipose tissue. It was 
previously believed that fetal oxidation of lipids did not exist, due to lack of machinery available 
during gestation and the presence of malonyl CoA, which can indirectly inhibit β-oxidation. 
However, recent work has detected both the activity of enzymes involved in fatty acid oxidation 
and presence of different acylcarnitine species in human fetal tissues (Oey et al., 2006; Rebholz 
et al., 2011). Perturbations of lipid oxidation also greatly affect fetal growth, leading to smaller 
fetal sizes or lethality.   
 
Protein metabolism 
For both glucose and fat metabolism, adaptations during pregnancy are made in response 
to existing maternal needs. However, the same is not true for protein metabolism (Kalhan, 2000). 
Most of the adaptations made are in anticipation of maternal and fetal needs later on as protein 
metabolism changes early in gestation before fetal growth has drastically increased. What is 
similar between glucose, fat and protein metabolism is that the end goal is to conserve energy in 
order to provide for the fetus. There are two ultimate paths for amino acids – they can be either 
oxidized or stored in tissues. Most amino acids in pregnancy are used for protein synthesis, as the 
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mother undergoes significant increases in tissue volume. Though there is a net increase in protein 
storage, there is also an observable decrease in oxidation or catabolism of amino acids that is 
detected by urea synthesis. Using stable isotope tracers in mice, an approximately 30% decrease 
in the rate of urea synthesis is observed in the first trimester, and 45% decrease by the third 
trimester (King, 2000).   
Along with glucose, amino acids are another source of substrate for the fetus, accounting 
for approximately 20% of energetic needs. Thus, maternal metabolism diverts usage of amino 
acids to facilitate the needs of the fetus. As expected, serum levels of amino acids decrease 
during pregnancy, and fasting induces hypoaminoacidemia and a reduction in gluconeogenic 
amino acids (Felig et al., 1972; Schoengold et al., 1978). Furthermore, branched chain amino 
acid (BCAA) oxidation is also decreased during late pregnancy (Kalhan et al., 1998).  
 
Profound maternal adaptations occur to cater to the needs of the fetus. Early pregnancy is 
an anabolic environment, while late pregnancy is catabolic, all to satisfy fetal demands. Glucose, 
lipid, and amino acid levels change to prioritize fetal consumption of glucose (Figure 1.1). Much 
of the molecular mechanisms responsible for these alterations are unknown and not well studied, 
though the hormonal milieu has been independently found to be associated with many of these 
metabolic changes.   
 
Normal cardiac metabolism  
Every second of every day, the heart is dutifully working, pumping blood and nutrients 
out to supply energy to the rest of the body. Any breach to this fidelity and catastrophic disaster  
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Figure 1.3: Normal cardiac metabolism. Under normal physiological conditions, 
cardiomyocytes use approximately 70% fatty acid as substrate sources and 30% glucose as 
substrate sources. Glucose enters the cell via glucose transporters, such as GLUT4, and then 
undergo glycolysis to form pyruvate that is then converted to acetyl CoA. Pyruvate can also 
be converted to lactate that can exit the cell, but lactate can also be taken up by 
cardiomyocytes to form pyruvate. Similarly, fatty acids enter the cell through their respective 
transporters, such as CD36, and ultimately is transported to the mitochondria to undergo β-
oxidation to form acetyl CoA. Acetyl CoA then enters the TCA cycle, which creates and 
donates reducing equivalents in the form of NADH and FADH2 to the ETC. Electron transfer 
through the ETC leads to creation of a proton gradient that ultimately leads to the production 
of ATP by ATP synthase. Due to the high energy demands of the heart, regulation of these 
pathways can occur at many locations to ensure that constant supply of substrates is always 
met. Different points of regulation are marked with numbers 1-5: (1) transporter localization; 
(2) phosphofructokinase-1 (PFK-1); (3) pyruvate dehydrogenase (PDH); (4) lipoprotein lipase 
(LPL); and (5) malonyl CoA concentrations.  
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Figure 1.3 (continued)  
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could occur. Thus, it is vitally important that the myocardium fully satisfies its demands. The 
heart has extremely high energetic needs, the highest amongst all the organs. This is especially 
critical given its low energy reserves and complete ATP turnover every 10 seconds. Tight 
metabolic regulation is therefore also necessary to ensure that depletion of energy resources 
never occurs. There are many facets of regulation, including gene transcriptional control, post-
translational modifications, allosteric alterations to critical enzymes, the relative concentrations 
of substrates to products, level of hormones present in the plasma, and transporter localization in 
the cell (Kolwicz et al., 2013; Lopaschuk et al., 2010; Stanley et al., 2005).  
Thankfully, the heart is “omnivorous”, and is able to utilize many different substrates as 
energy sources. This means that under conditions of stress or disease, when glucose or fat may 
become limited, the heart is able to continue its high energy output by using other substrates, 
such as ketone bodies during starvation, amino acids during ischemia, and lactate during exercise 
(Drake et al., 2012; Gertz et al., 1988; Gold and Yaffe, 1978; Mazer et al., 1990; Stanley, 1991). 
However, in times of nutrient abundance, the myocardium metabolizes predominantly fatty 
acids, approximately 60-90%, and satisfies the remaining 10-40% from glucose (Bing et al., 
1954). Furthermore, approximately 95% of the ATPs generated are by oxidative phosphorylation 
in the mitochondria, highlighting the importance of this organelle to sustaining energy needs. 
The ATPs generated are then used mainly for contractility and to power calcium ATPases and 
ion pumps.  
To fully understand how the heart preferentially utilizes its substrate sources, it is useful 
to review basic metabolism (Figure 1.3). Glycolysis and fatty acid β-oxidation all converge on a 
single mitochondrial substrate, acetyl CoA that then enters the tricarboxylic acid (TCA) cycle. 
However, their beginnings are very different. The source substrates for glycolysis are exogenous 
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glucose, which can enter the cell via specialized glucose transporters (GLUTs), of which GLUT4 
and GLUT1 are the predominant myocardial GLUTs, or stored glycogen, which can be broken 
down to glucose-6-phosphate to enter glycolysis (Bell et al., 1990). As the glycogen storage pool 
in the heart is very small and has a rapid turnover, the primary cardiac glycolytic substrate is 
exogenous glucose (Goodwin et al., 1995; Henning et al., 1996). The net result of glycolysis, 
which occurs in the cytosol, is two molecules of ATP, pyruvate and NADH. It has been shown 
that most glycolytic enzymes reside near the sarcolemmal membrane and the sarcoplasmic 
reticulum (SR), and that the ATP generated from glycolysis is preferentially used for ion 
channels at these locations (Xu and Becker, 1998; Xu et al., 1995). The end metabolite of 
glycolysis is pyruvate, which then has three fates: (1) to be converted to lactate and subsequently 
secreted from the cell; (2) to enter the mitochondria via pyruvate carriers and be decarboxylated 
to acetyl CoA; or (3) to be carboxylated to TCA intermediates oxaloacetate or malate, a process 
known as anaplerosis, which accounts for ~5% of flux through the TCA cycle (Brin and Olson, 
1952; Smyth, 1940; Spydevold et al., 1976). The purpose of anaplerotic reactions is to replenish 
and maintain the pool of intermediates available in the TCA in the face of cataplerotic exit.   
Fatty acids, on the other hand, arrive at acetyl CoA through a different pathway (Su and 
Abumrad, 2009). First, as extremely hydrophobic entities, they are unable to travel alone – thus, 
they enter either bound to albumin or more commonly, in lipoproteins. Lipoprotein lipases (LPL) 
on the surfaces of endothelial cells can hydrolyze triglycerides to extract fatty acids, which can 
then enter the cardiomyocyte (Pulinilkunnil and Rodrigues, 2006). There are four factors on the 
membrane to facilitate uptake, including a fatty acid translocase (FAT), called CD36, the plasma 
membrane fatty acid binding protein (FABPPM), fatty acid transport proteins 1/6 (FATP1/6), and 
fatty acyl-CoA synthase (FACS) (Ellis et al., 2011; Gimeno et al., 2003; Goldberg et al., 2009; 
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Paul et al., 2014; Schaap et al., 1999; Sorrentino et al., 1988). The presence of FACS on the 
membrane allows rapid esterification of the incoming fatty acid. Once inside the cell, the fatty 
acid has two fates: storage as triglycerides, which occurs to approximately 20% of the incoming 
fatty acids, or continuation on the path towards β-oxidation. To do the latter, the fatty acid must 
enter the mitochondria, where β-oxidation takes place. This occurs via a carnitine-based 
transporter system that includes various enzymes and carriers, including carnitine 
palmitoyltransferase I (CPT-I), a heavily regulated enzyme located on the outer mitochondrial  
membrane, and CPT-II, located on the inner mitochondrial membrane (Bremer, 1983). The end 
product is the presence of long chain acyl CoAs in the mitochondria, where they can then 
undergo β-oxidation to create acetyl CoAs, NADH, and FADH2.  
Acetyl CoA formed from both glycolysis and fatty acid oxidation enters the TCA cycle, 
where it produces reducing equivalents in the form of NADH and FADH2 that act to deliver 
electrons to the electron transport chain (ETC) located on the inner mitochondrial membrane 
(Stanley et al., 2005). The donation of electrons to the ETC couples the reduction of oxygen into 
water to generate a proton gradient that ultimately powers the ATP synthase to form ATP from 
ADP. This ATP is then used to power the cardiomyocyte for many different processes. Thus, the 
complete oxidation of glucose through aerobic metabolism generates >30 molecules of ATP, 
compared with the two molecules that form from glycolysis alone.  
 
Regulation of cardiac metabolism 
In order to ensure constant substrate supply to the heart, regardless of stress or external 
environment, many regulatory points exist in these metabolic pathways (Figure 1.3). First, the 
levels of substrate availability greatly determine usage – for example, fatty acid concentrations 
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can range from 0.2-0.8 mM throughout the course of a day (Dole, 1956). Furthermore, during 
conditions of ischemia, early starvation, or diabetes, levels can increase to greater than 1.0 mM 
(Gold and Yaffe, 1978; Roy et al., 2013; Yi et al., 2006). Elevated concentrations of fatty acids 
can compete with glucose for substrate uptake, through the “Randle cycle” or the “glucose-fatty 
acid cycle,” in which elevated fatty acid oxidation rates can decrease glycolysis. Conversely, 
decreases in plasma fatty acid concentrations will activate oxidation of pyruvate. Secondly, the 
transporters that are responsible for uptake of substrates are also regulated by their localization. 
CD36 and GLUT4 are normally located in intracellular vesicles and upon stimulation with 
insulin or contraction, can travel to plasma membranes, to allow uptake of their corresponding 
substrates (Bonen et al., 2000; Boucher et al., 2014; Gimeno et al., 2003; Luiken et al., 2002a; 
Slot et al., 1991). Many signaling pathways regulate transporter localization. The PI3K/Akt 
pathway, for example, has been well studied to trigger GLUT4 vesicle translocation upon 
activation by insulin signaling (Matsui et al., 2001; Walsh, 2006). The AMP-activated protein 
kinase (AMPK) pathway is another that is critically involved in sensing nutrient status and 
responding accordingly (Zaha and Young, 2012). Known as the “cellular fuel gauge,” it is a 
pivotal defense against cellular stresses. For example, upon detecting high ratios of AMP/ATP, 
ADP/ATP, or Cr/PCr, AMPK will then phosphorylate downstream targets, including the 
GTPases that control GLUT4 and CD36 vesicle fusion in order to promote plasma membrane 
localization of transporters (Chavez et al., 2008; Thong et al., 2007). In addition, AMPK can 
inhibit endocytosis of GLUT4 or CD36-containing vesicles (Yang and Holman, 2005).  
Another regulatory point is through pivotal enzymes in metabolic pathways to control 
flux. For example, phosphofructokinase-1 (PFK-1), a glycolytic enzyme involved in the first 
irreversible step of glycolysis to make fructose-1,6-bisphosphate (F-1,6-BP), is activated by ADP 
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and AMP, but inhibited by ATP, citrate, and its end product, F-1,6-BP (Mor et al., 2011). 
Hormones, such as insulin, glucagon, and epinephrine, are also known to regulate its activity, as 
well as post-translational modifications, such as phosphorylation by AMPK (Marsin et al., 2000). 
Pyruvate dehydrogenase (PDH), another critical enzyme, catalyzes the conversion of pyruvate to 
acetyl CoA (Kobayashi and Neely, 1983a, b). This enzyme is instrumental in regulating the entry 
of carbons into the TCA cycle from glycolysis, and is itself regulated by a family of kinases and 
phosphatases (Jeoung and Harris, 2010; Zhang et al., 2014). The pyruvate dehydrogenase kinase 
(PDK) family, of which PDK2 and PDK4 are most prominently expressed in the heart, can 
phosphorylate and inactivate PDH to block pyruvate contribution to the TCA cycle (Holness and 
Sugden, 2003). It is a key step in shifting the contribution of carbons from glycolysis to that of 
fatty acid oxidation. PDK4 is known to be regulated by many processes. States of starvation, 
diabetes, and hypoxia, in which FFA are in abundant, activate PDK4 to inhibit pyruvate 
conversion to acetyl CoA (Razeghi et al., 2001; Wu et al., 1998). Conversely, states in which 
there are decreases in the acetyl CoA:free CoA or NADH:NAD+ ratios inhibit PDK4 to activate 
PDH (Lee et al., 2004).  
Enzymes in the fatty acid oxidation pathway also are subject to regulation as well. For 
example, the activity of LPL determines the fat uptake status of the heart (Augustus et al., 2004). 
In nutrient states in which there are greater fatty acid oxidation, such as diabetes or starvation, 
elevated activity and levels of cardiac LPL is observed on the endothelial lumen (Kersten, 2014; 
Kotlar and Borensztajn, 1977; Sugden et al., 1993). AMPK can also increase the amount of LPL 
present on the endothelium (An et al., 2005). CPT-I, which is involved in the formation of long 
chain acylcarnitines, is another critical point of control. Malonyl CoA binds to and strongly 
inhibits CPT-I, acting as a negative regulator of fatty acid oxidation (Foster, 2012; McGarry et 
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al., 1977). Malonyl CoA has an extremely rapid turnover time, with a half-life of approximately 
1.25 minutes. Thus, when levels of malonyl CoA decrease, rates of fatty acid oxidation increase. 
Carboxylation of cytosolic acetyl CoA by the enzyme acetyl CoA carboxylase (ACC) forms 
malonyl CoA, and decarboxylation of malonyl CoA by malonyl CoA decarboxylase (MCD) 
creates more acetyl CoAs. Mouse models with genetic ablation of ACC increase oxidation of 
fatty acids, as expected due to decreased malonyl CoA levels (Kolwicz et al., 2012). AMPK can 
phosphorylate and inhibit ACC, preventing malonyl CoA formation to augment fatty acid 
oxidation (Park et al., 2002).  
Nitric oxide (NO) has also been shown to have direct effects on cardiac metabolism. In 
addition to its known role as a vasodilator, many studies have found that NO can directly alter 
substrate usage. Infusion of dogs with L-NAME, an inhibitor of NO, for 10 days increased 
glucose oxidation, while decreasing fatty acid oxidation (Recchia et al., 1999; Recchia et al., 
2002). In addition, hearts from eNOS-deficient mice increase glucose uptake (Tada et al., 2000). 
Consistent with all this, dogs treated with a NO donor, nitroglycerin, had blocked AMPK-
induced GLUT4 translocalization during ischemic insult.   
Another vital point of regulation is transcriptional regulation of metabolic genes (Leone 
and Kelly, 2011). The family of nuclear receptor transcription factors collectively known as the 
peroxisome proliferator-activated receptors (PPARs) has been well characterized in terms of 
their contribution to cardiac flux control. The three members of the PPAR family are PPARα, 
PPARβ/δ, and PPARγ, of which PPARα is best known to upregulate fatty acid oxidation genes 
in the heart. When PPARα is upregulated, genes involved in all facets of fatty acid uptake and 
oxidation are concurrently induced, including CD36, FATP1, FABP, FACS, MCD, CPT-I, and 
PDK4. Mice with deletion of PPARα show decreased expression of fatty acid genes and 
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decreased fatty acid oxidation (Gilde et al., 2003). Conversely, overexpression of PPARα shows 
an increase in fat uptake, oxidation, and cardiac lipotoxicity (Barger et al., 2000). The PPARs are 
also known to be activated by another well-characterized family of transcriptional coactivators, 
the PGC-1 (PPARγ coactivator 1) family, of which PGC-1α is the best studied member (Rowe et 
al., 2010). PGC-1α can activate mitochondrial biogenesis, fatty acid oxidation and oxidative 
phosphorylation by co-activating with multiple transcription factors, including ERRs and PPARs 
(Patten and Arany, 2012; Russell et al., 2004). Though mice with cardiac-specific deletion of 
PGC-1α have normal mitochondrial content, they still have decreased oxidative phosphorylation 
and contractile function (Arany et al., 2005). Furthermore, they also develop heart disease during 
pregnancy, similar to a clinical condition known as peripartum cardiomyopathy (PPCM).  
Changes in substrate utilization occur during neonatal development and in certain disease 
states. For example, embryonic and fetal cardiac development are both characterized by a 
dependence on glycolysis and lactate production (Lopaschuk and Jaswal, 2010). There is very 
little detectable fat usage. It is not until 7 days after birth that a shift occurs in substrate 
preference, more closely matching what is observed in adult hearts (Taegtmeyer et al., 2010). 
PPARα, PGC-1α, and AMPK expression levels parallel the increase in fat consumption. During 
diseased states, another substrate change, known as “fetal shift,” is a hallmark of heart failure. 
Human positron emission tomography (PET) studies of heart failure patients have shown a 
decreased utilization in fatty acids and an increase in glucose (Davila-Roman et al., 2002; Yazaki 
et al., 1999). Much work has gone into understanding how this shift occurs and whether it is a 
beneficial or maladaptive response.  
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Myocardial and hemodynamics alterations in pregnancy 
Maternal systemic metabolism undergoes major shifts in order to facilitate the growing 
needs of the fetus. This is reflected in the adaptations that occur in cardiac metabolism, both in 
response to fetal demands and also increased demands for cardiac work (Melchiorre et al., 2012). 
Though there have been many studies devoted to characterizing the hemodynamic changes that 
occur throughout pregnancy, many discrepancies have been observed, owing to varying methods 
of data collection and analysis (Bamfo et al., 2007; Turan et al., 2008; Zentner et al., 2009). For 
example, the small sample size of many studies have led to conclusions that may be more 
indicative of individual profiles rather than the collective majority. Furthermore, different 
measurement tools/methods or inconsistent use of controls, such as non-pregnant, early 
pregnancy or post-partum stages, have also contributed to contradicting conclusions (Hinderliter 
et al., 1992; Masaki et al., 1989; Volman et al., 2007). Thus, it is important to understand the 
exact experimental parameters of each experiment before making conclusions. 
Even though there is variability in hemodynamic measurements during pregnancy, some 
parameters are consistent and reproducible. An increase in preload is seen, owing to the rise in 
blood volume, which contributes to the “physiological anemia” of pregnancy. There is also a 
concomitant decrease in afterload, in accordance with decreases in systemic vascular resistance 
(SVR) and mean arterial pressure (MAP) starting in the fifth week of pregnancy and peaking at 
the beginning of the third trimester (Capeless and Clapp, 1989; Gilson et al., 1997; Savu et al., 
2012). The hormonal environment has been hypothesized to be responsible for the alterations in 
preload and afterload. For example, vasodilators, such as NO and prostaglandins, have been 
shown to decrease peripheral resistance (Anderson et al., 1976; Haynes et al., 1993; Shaamash et 
al., 2000).  
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Other cardiac parameters, such as cardiac output, have been extremely well characterized 
and found to be consistent among different studies (Figure 1.4). Beginning as early as the fifth 
week of pregnancy, cardiac output starts to increase, rising to as much as 50% above baseline at 
its peak around mid to late pregnancy (Capeless and Clapp, 1989; Gilson et al., 1997; Hunter and 
Robson, 1992; Mabie et al., 1994; Mone et al., 1996; van Oppen et al., 1996). By two weeks 
postpartum, this effect is reversed. Cardiac output measurements are secondary to heart rate and 
stroke volume, which increase by approximately 15-30% and 15-25% at their peak, and also 
return to normal by 10-14 days postpartum. Systolic blood pressure, on the other hand, has been 
shown to stay constant throughout most of pregnancy while diastolic blood pressure decreases 
initially, is stable or slightly decreases throughout the second trimester, and finally increases near 
Figure 1.4: Hemodynamics changes during pregnancy. Cardiac output, heart rate, stroke 
volume, and blood volume all increase between 5 and 8 weeks of gestation, peak by mid-
pregnancy, and is sustained until the end of pregnancy. These parameters are reversed by 6 
months postpartum. 1, Clark et al., 1989; 2, Hytten and Paintin, 1963.  
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the end of pregnancy (Atkins et al., 1981; Delachaux et al., 2006; Desai et al., 2004; Mabie et al., 
1994; Mone et al., 1996; Volman et al., 2007; Zentner et al., 2009).  
The discrepancies in hemodynamics studies surround systolic and diastolic cardiac 
function. Diastolic function is less studied, and different studies have come to divergent 
conclusions. Some have shown no alterations in diastolic function, while others have reported 
decreases by late pregnancy (Bamfo et al., 2007; Kametas et al., 2001; Mesa et al., 1999; 
Valensise et al., 2000; Zentner et al., 2009). Systolic function, as indicated by ejection fraction 
and fractional shortening, is better studied. However, increases, decreases, and no change have 
all been observed (Desai et al., 2004; Pandey et al., 2010; Valensise et al., 2000). Thus, these 
cardiac parameters are currently incompletely defined.  
Structural and morphological changes also occur during pregnancy (Chung and 
Leinwand, 2014). By late gestation, enlargements in all four chambers of the heart are observed. 
Furthermore, wall thickness and mass also increase, as well as the size of all the valves. 
Eccentric cardiac hypertrophy has also been noted, due to the prolonged cardiac volume overload 
(Estensen et al., 2013). Individual cardiomyocyte size also increases with significant elongation 
observed in cardiomyocytes isolated from pregnant mouse hearts. The Akt/PI3K pathway, which 
is known to play a role in other cardiac hypertrophy models, is upregulated in mid-pregnancy 
and is sustained to the end of pregnancy (Chung et al., 2012b). Progesterone treatment of 
neonatal cardiomyocytes increases cell size, suggesting that hormones could be responsible for 
these adaptations. Blockage of MEK1 abrogated this effect, indicating that the cardiac 
hypertrophy of pregnancy is mediated through Akt and MEK1 pathways. One study found that 
the potassium channel Kv4.3 is downregulated during pregnancy, resulting in longer QT 
intervals and the tyrosine kinase c-Src is upregulated, contributing to cardiac hypertrophy of late 
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pregnancy (Eghbali et al., 2005). Ovariectomized mice treated with estrogen reproduced the 
pregnancy effects of Kv4.3 and c-Src, which was reversed by a receptor antagonist.  
The molecular mechanisms underlying cardiac remodeling during pregnancy have also 
been studied (Chung et al., 2012b). The classical markers of pathological hypertrophy, such as 
the ratio of α-myosin heavy chain (MHC):β-MHC, skeletal α-actin, and atrial natriuretic factor 
(ANF), are unchanged during pregnancy. Furthermore, no cardiac fibrosis is detected in the 
pregnant heart as seen in the diseased heart.  
 
Cardiac metabolism changes during pregnancy 
The metabolic adaptations of the heart during pregnancy are not well characterized. 
However, a similar theme of forgoing energy sources to suit the needs of the fetus is present. The 
first experiments to study cardiac metabolism during pregnancy involved [3H]-2-deoxyglucose 
tracer injections in rats to determine glucose utilization. The studies found decreases of 46% 
around mid-pregnancy (day 15), ultimately lowering to 74% by late pregnancy (day 20) (Sugden 
et al., 1992). Conversely, the same group also observed an increase in fatty acids and ketone 
bodies in late pregnant serum, but did not detect differences in cardiac PDH activity (Sugden and 
Holness, 1993a, e). More recently, studies found an increase in cardiac NO synthesis and eNOS 
expression in late pregnant dog hearts (Williams et al., 2008; Williams et al., 2007). This is 
accompanied by a decrease in glucose uptake and a corresponding increase in fatty acid uptake. 
Treatment with L-NAME reversed the effects seen, leading the group to conclude that NO plays 
a role in the substrate switch of late pregnancy. However, the precise mechanism is not known.  
Mechanisms explaining this substrate switch are not fully understood. As mentioned 
previously, in one study, PDH activity is unchanged. Mitochondrial morphology remains normal 
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during pregnancy, as observed with confocal microscopy (Bassien-Capsa et al., 2006). The 
drastic decrease in glucose utilization does not match the small decrease in serum glucose levels. 
Furthermore, two studies in rats found no change in GLUT4 or PDK4 expression in late 
pregnancy (Nieuwenhuizen et al., 1998; Rimbaud et al., 2009).   
The hormonal state of pregnancy could regulate the substrate switch that is observed. 
Most studies on the effects of estrogen on metabolism are in the context of hormone replacement 
therapy, but evidence of estrogen increasing fatty acid uptake is observed with PET (Herrero et 
al., 2005). In addition, estrogen also can increase both eNOS and NO levels. Furthermore, male 
mice with PPARα deletion have massive cardiac lipotoxicity that ultimately resulted in early 
mortality (Djouadi et al., 1998). However, estrogen supplementation in these mice rescued the 
phenotype, suggesting the importance of estrogen in regulating fatty acid utilization.  
Thus, much work still needs to be accomplished in characterizing the metabolic changes 
in response to pregnancy.  
 
Cardiac diseases during pregnancy 
How do insufficient maternal metabolic adaptations during pregnancy lead to disease? In 
particular, can complications arise from deviant cardiac metabolism? Pregnancy is considered a 
stress test to the body, both exacerbating known problems and unmasking unknown 
complications. Gestational diabetes is characterized by the intolerance of glucose during 
pregnancy, which can be a result of the lack of β-cell changes in response to the insulin 
resistance environment of pregnancy. Preeclampsia, a disease that manifests in late pregnancy, is 
characterized by high blood pressure and proteins in the urine (Powe et al., 2011). In recognizing 
the effects of aberrant pregnancy alterations on the heart, the American Heart Association (AHA) 
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recently added diseases of pregnancy, such as preeclampsia, gestational diabetes, and pregnancy 
induced hypertension, as risk factors for cardiovascular disease (CVD) (Intapad and Alexander, 
2013a, c). A woman who has had preeclampsia has double the risk of CVD approximately 5-15 
years post-delivery. Could these derangements of pregnancy affect cardiac metabolic responses 
that manifest as CVD post pregnancy? The cardiac metabolic effects from these diseases have 
not been well studied.  
The stress on cardiac function during pregnancy is also capable of revealing latent 
cardiac vulnerabilities. Women who have had a myocardial infarction during pregnancy have 
worse long term prognosis than those who have not (Kealey, 2010; Roth and Elkayam, 1996). In 
addition, pregnant mouse hearts undergoing ischemia/reperfusion injury show increased infarct 
sizes compared to non-pregnant controls (Li et al., 2012). The underlying mechanisms are 
unexplored, but the increased reliance on fatty acids during pregnancy could result in an inability 
of the heart to adapt when necessary to other insults. 
A pregnancy-associated disease that directly affects cardiac capacity is peripartum 
cardiomyopathy (PPCM), a rare (affecting 1:300-1:3000 of live births) but deadly condition that 
occurs during late gestation or immediately postpartum (Bello et al., 2013). It is diagnosed by 
systolic heart failure in otherwise healthy women. Recent studies have pointed towards vascular 
insufficiency as the cause for PPCM, perhaps with a metabolic deficiency undertone. In mouse 
studies, cardiac deletion of the transcription factor STAT3 leads to PPCM (Halkein et al., 2013; 
Hilfiker-Kleiner et al., 2007). Prolactin, a hormone secreted in late pregnancy, is abnormally 
cleaved to a 16 kDa anti-angiogenic fragment by unregulated reactive oxygen species (ROS) 
response. Clinical trials with an inhibitor of prolactin secretion, bromocriptine, has showed 
promising but limited results. Another study corroborating vascular deficits of PPCM was in 
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mice with cardiac deletions in PGC-1α (Patten et al., 2012). As previously described, PGC-1α is 
a transcriptional co-activator known to regulate mitochondrial biogenesis, fatty acid oxidation, 
and the angiogenetic response. Female mice without PGC-1α become even more vulnerable to 
the anti-angiogenic environment of late pregnancy, and develop PPCM. Cardiac function was 
fully rescued with injections of bromocriptine and VEGF, suggesting that both models share a 
similar vascular dropout pathway.  
How aberrant cardiac metabolic adaptations can contribute to PPCM has not been 
explored. The vascular deficiency state of PPCM (as seen in both STAT3 and PGC-1α knockout 
models) suggests that there is also an inadequate supply of nutrients and fuel to the cardiac 
tissues. In addition, PGC-1α is known to regulate PPARα, an important regulator of fat 
utilization, and depletion of PPARα could be detrimental to cardiac function. However, how this 
mechanism can be extrapolated to human PPCM is unknown.  
 
Conclusion 
 Intense metabolic alterations occur during pregnancy, all in response to fetal demands for 
glucose. Systemic insulin resistance defines maternal metabolism. The heart also adopts this 
switch, although the regulatory mechanism for this have not been thoroughly explored. 
Understanding what contributes to metabolic flux control can have significant implications in 
pregnancy-associated cardiac diseases, including PPCM. We thus propose to examine in this 
thesis the maternal cardiac metabolic adaptations that occur during pregnancy in mice.  
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All figures, tables and portions of the text were adapted from:  
Liu, L.X., Arany, Z. (2014). Maternal cardiac metabolism during pregnancy. Cardiovasc Res. 
101(4): 545-553. 
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Abstract 
During pregnancy, the maternal myocardium makes adaptations to facilitate fetal needs 
for glucose. Little is known about the exact metabolic nature of the heart in pregnancy. We 
propose to characterize the cardiac energetic state of late pregnancy. Serum triglyceride profiles 
increase in mid- and late pregnancy, but no change in serum glucose levels is observed. 
Furthermore, import of fat into late pregnant mouse hearts was elevated compared to non-
pregnant. Using metabolic tracer studies, we found that late pregnant mouse hearts are 
metabolically defined by a ~50% decrease in glucose usage, and accompanied by a ~20% 
increase in fatty acid utilization. These data indicate occurrence of intrinsic cardiac adaptations 
that result in a substrate switch in late pregnancy.   
 
Introduction 
Hormones, cytokines, chemokines, and metabolites are continuously secreted into the 
blood in response to a dynamic physiological milieu. Integration of these signals leads to 
complex responses. Understanding these responses can provide mechanistic details vital to how 
we view these many processes, and impact how we develop therapeutics to different diseased 
states.  
There is a dramatic change in metabolic demand and use during pregnancy - increasing 
maternal insulin resistance throughout gestation, and switching preference away from glucose to 
allow fetal consumption (King, 2000). It is known that the heart adopts similar adaptations 
during pregnancy, but much still remains unanswered. The exact metabolic state of the heart in 
pregnancy in mice remains to be fully characterized (Liu and Arany, 2014). Furthermore, how 
this metabolism changes during diseased states such as gestational diabetes, preeclampsia, or 
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peripartum cardiomyopathy (PPCM) has never been studied. Gestational diabetes and 
preeclampsia are both known to increase risk for cardiovascular disease (CVD) 10-15 years post-
delivery (Intapad and Alexander, 2013a). The metabolic cardiac insults that occur during 
pregnancy are not known. In addition, previous work has pointed to PPCM being a vasculo-
metabolic disease, and whether metabolic dysfunction precedes disease phenotype is unknown 
(Hilfiker-Kleiner et al., 2007; Patten et al., 2012). Examination into this could potentially provide 
a new therapeutic perspective to treating these diseases. Therefore, characterization of metabolic 
changes in the heart is the first step in understanding what happens in normal, and eventually, 
abnormal pregnancy.   
 
13C metabolic flux analysis 
There are many ways to paint a picture of the metabolic profile of a cell or tissue under 
various conditions (Metallo and Vander Heiden, 2013). For example, measurements of the rates 
of metabolite influx or efflux, intracellular concentrations of intermediates, kinetics of each 
metabolic pathway, or downstream signaling targets all illuminate the state of the cell. Each 
study conducted in isolation could lead to incomplete conclusions. Cellular uptake assays or 
conditioned media detection assays do not provide information about the usage of a metabolite 
per se, but rather a broad overview of the entrance and exit. Proteomics and metabolomics can 
determine the abundance of proteins and metabolites in different pathways, but yield stationary 
images of the energetic state of the cell. There is no information gleaned about kinetics of 
different pathways or the direction of metabolite flow. For example, a decreased abundance of a 
metabolite could signal a decrease in synthesis or increase in consumption – two very different 
endpoints. More recently, the use of stable-isotope tracers, such as 13C or 15N, has gained traction 
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due to the advance of mass spectrometry (MS) and nuclear magnetic resonance (NMR). The 
power of these tracers lies in their ability to give time-dependent flux information. Thus, 
integrating metabolomics with different tracer studies could paint a more complete metabolic 
imagery.   
The work flow of flux analysis is relatively simple, although key principles must be 
satisfied (Zamboni and Sauer, 2009). First, a type of tracer must be chosen. Currently, stable 
isotope tracers have greatly facilitated experimental design. The advantages of stable isotope 
tracers over previously popular radioisotopes (most commonly used were 14C and 3H) has led to 
more robust flux analysis (Coggan, 1999). Radioisotope measurements are made in response to 
the radioactive decay of an unstable nucleus and can be very sensitive. However, in addition to 
the costs and safety of handling radioactive materials, quantification of activity is observed in the 
byproducts produced from reactions, such as 3H2O or 
14CO2, which does not allow recycling 
back to the parent compound. The metabolic rates determined by radioactively labeled substrates 
are absolute rates. Stable isotopes, on the other hand, as the name suggests, do not decay and are 
typically one or two mass numbers heavier than the most abundant stable isotope, which makes 
them a suitable target for detection by mass spectrometry though relative metabolic rates are 
determined.  
Choosing the type of stable isotope tracer to use is a key component of 13C tracer 
analysis. Beginning with 13C-glucose, 13C-pyruvate, 13C-lactate, or 13C-fatty acids can enlighten 
rates through different pathways. For example, studies using 13C-lactate, 13C-pyruvate, and 13C-
glucose in ex vivo perfused mouse hearts determined a constant influx and efflux of exogenous 
lactate and pyruvate, though preference is for the uptake of pyruvate over lactate (Khairallah et 
al., 2004). Furthermore, exogenous lactate contributes more to the pyruvate pool, approximately 
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42%, than any other carbohydrate. In addition to selection of the metabolite tracer, the number of 
heavy isotopes can also provide valuable information (Metallo and Vander Heiden, 2013). For 
example, the pentose phosphate pathway (PPP) is often studied with 1,2-13C2-glucose, that is 
heavy isotope labeling of the first and second carbons of glucose. If flux through PPP is 
observed, then loss of the first labeled carbon would be seen in the metabolites of glycolysis, 
whereas if flux does not occur through PPP, both carbon would be labeled in the glycolytic 
intermediates (Brekke et al., 2014).  
Applications of stable isotope labeling can be employed in many models, including 
whole animals, ex vivo perfused organs, or in cell culture (Vaillant et al., 2014; Yi et al., 2006). 
After incubation or perfusion with the labeled substrate (in which conditions should mimic 
physiology in concentration and availability of multiple energy sources), samples are quickly 
frozen to ensure that no metabolic alterations can occur post treatment. Then, metabolites from 
the source tissue or cell are isolated and introduced to the detection system, with either MS or 
NMR as previously mentioned (Des Rosiers et al., 2004; Fan and Lane, 2011). There is more 
widespread use of MS, due to the fact that it is cheaper, more sensitive (can detect in the pmol to 
nmol range in contrast to NMR which can detect µmol to mmol range), and more expansive in 
metabolite detection. Furthermore, MS offers the additional benefit of being able to determine all 
the mass isotopomers of each metabolite, including the unlabeled component. NMR, on the other 
hand, measures the positional isotopomer. The power of NMR is in its ability to make dynamic, 
real-time measurements, while MS is based on single, terminal time point. Ideally, a combination 
of NMR or MS methods can provide a clearer picture, but practically speaking, MS has many 
advantages that we utilize in our experiments as well, so we will focus here mostly on MS 
methods of metabolite detection. 
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After extraction of metabolites, the samples are injected into the mass spectrometer, 
where it is ionized into fragments that are then sorted based on their mass to charge (m/z) ratio. 
That ratio is recorded as a spectrum. It is important that the crude measurement is corrected for 
natural abundance, which for 13C is 1.11% and 0.365% for 15N (Buescher et al., 2015). The 
relative distribution of the mass isotopomers can then denoted as mn (or m+n), where n is the 
number of 13C in the isotopomer. For example, in the case of glucose, its labeling will begin with 
m+0, for the unlabeled 12C species, and up to m+6, for six labeled carbons. The mass isotopomer 
representation is of the fractional abundance of each of species of isotopomer over all species: 
 
   Fractional Abundance of each isotopomer = 
𝑚(0,1…𝑛)
𝑚0+𝑚1+⋯+𝑚𝑛
 
 
Figure 2.1 shows the mass isotopomer distribution for a given TCA metabolites, with either 
uniformly labeled glucose or fatty acid. The potential isotopomer species for the intermediates 
from the first and second turn of the TCA cycle are shown, such that the second turn combines 
with a fully labeled acetyl CoA, although depending on the perfusion environment, could be just 
as if not more likely for an unlabeled acetyl CoA to combine with the m+2 oxaloacetate.  
While this strategy for studying metabolic flux yields a more vivid image than previous 
techniques, there are still limitations (Buescher et al., 2015). First, compartmentalization within 
cells can be confounding, as there are no ways to differentiate between subcellular localization. 
Metabolites are also known to traverse subcellular spaces, but current flux analyses characterize 
whole cell fluxes. Second, the technique is only as useful as the design. Thus, if only 13C-glucose 
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was used, the results will paint an incomplete picture, and so it is important to use multiple 
labeled sources, and also concurrently provide both physiological concentrations and varieties of 
metabolites. For example, our studies use both 13C-glucose and 13C-fat to characterize the 
metabolic state of late pregnant mouse hearts. This provides a more completely, though not 
wholly sufficient, profile of substrate utilization.  
Figure 2.1: 13C-metabolic flux analysis. Perfusion with U-13C-glucose or U-13C-palmitic acid 
yields m2 labeled acetyl CoA that then enters the TCA. Each cycle through the TCA produces 
different mass isotopomer species for each intermediate. After the first cycle (red), all TCA 
intermediates are m2 isotopomers, but after the second cycle (purple), depending on the 
location of the labeling, other isotopomer species are formed. Furthermore, if the second cycle 
incorporation is with an unlabeled acetyl CoA, different combinations of mass isotopomer 
would be observed (not shown here). Ultimately, a plot of the different mass isotopomer 
species for each metabolite can be plotted.  
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Langendorff perfusion studies 
There are many ways to characterize metabolism in late pregnant hearts, either via 
isolated cardiomyocytes, in the whole mouse, or ex vivo. Isolated adult cardiomyocytes do not 
survive long and are extremely sensitive to external conditions, and so can be physiologically 
irrelevant. Interpretations from whole animal studies are complicated by contamination by other 
organs and secreted factors. Ex vivo Langendorff perfusions are perhaps one of the most popular 
and simplest ways to study the heart without confounding elements.  
Developed by Oskar Langendorff in 1895, the principle behind this technique is 
relatively simple (Bell et al., 2011; Liao et al., 2012). Cannulation of the aorta provides 
retrograde perfusion to the heart. This closes the aortic valves and perfuses the coronary blood 
vessels. The perfusate travels from the coronary sinus to the right ventricle from the right atrium, 
before being drained through the pulmonary artery. Since then, others have added to this simple 
model to allow cardiac functional parameters to be measured, such as the addition of a water-
filled balloon connected to a pressure transducer that is then inflated inside the heart to determine 
left ventricular function. The heart is also paced to around 400 beats per minute. Thus, the 
Langendorff setup can be designed to create as close to the physiological environment of the 
heart in the whole body system as possible.  
Langendorff perfusion studies are at the core of many cardiac function and metabolism 
studies. For example, perfusing 13C-substrates into an ex vivo heart allows the investigator to 
have precise control over surrounding conditions. Oxygenating the solution with 95% oxygen, 
5% carbon dioxide can sustain cardiac function for hours in this model. Other applications, such 
as in ischemia/reperfusion during heart failure, have also readily used the Langendorff model to 
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answer mechanistic questions. How this model, along with metabolic flux analysis 
advancements, have contributed our understanding of cardiac metabolism is reviewed below.  
 
Cardiac metabolism and 13C flux analysis 
Langendorff perfusion of 13C-substrates, followed by NMR or MS detection, on normal 
and diseases hearts have elucidated much about how the heart utilizes substrates and how 
pathological conditions affect energy usage (Des Rosiers and Chatham, 2005). For example, 
detection of anaplerotic TCA intermediates (m3 isotopomers of oxaloacetate, fumarate or malate 
and absence of these species in succinate and α-ketoglutarate) has shown that anaplerosis 
contributes to approximately 10% of the flux through the TCA cycle (Des Rosiers et al., 2011; 
Nuutinen et al., 1981; Vincent et al., 2004; Vincent et al., 2003). In addition, it is possible to 
determine the source of anaplerosis as either pyruvate, glutamate, or propionyl CoA from β-
oxidation, with different 13C substrates (Lauzier et al., 2013). Contributions of anaplerosis to 
heart failure has also been explored. One group found an increase in the formation of malate 
from pyruvate (by malic enzyme) in pressure-overload hypertrophied hearts (Pound et al., 2009). 
This cytosolic malate then enters the mitochondria as an anaplerotic substrate via the 2-
oxoglutarate-malate carrier. Interestingly, this was also linked to decreased triglyceride 
synthesis, which was the result of a depletion of NADPH by malic enzyme.   
As an “omnivore,” the heart can use many different substrates. When it chooses to use 
one over another has been widely investigated with tracer studies. Fatty acids and glucose are the 
predominant substrates, but it was unclear how the heart uses other carbohydrates under normal 
conditions. 13C-pyruvate and 13C-lactate perfusion of the ex vivo heart, as mentioned above has 
demonstrated clearly that both are important contributors of carbon into the TCA (Khairallah et 
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al., 2004). In addition, using different forms of labeled fatty acids has elucidated much about 
fatty acid oxidation. For example, one study used 13C-oleate, 13C-docosanoate, and 13C-palmitate 
and discovered that peroxisomal β-oxidation plays a role in mitochondrial β-oxidation by the 
formation of malonyl CoA derived from peroxisomal acetyl CoA (Reszko et al., 2004).  
With genetically altered rodent models and metabolic flux analysis, much can be gleaned 
about cardiac changes during heart failure. For example, 13C-NMR of PPARα-null mouse hearts 
demonstrated a switch to glucose utilization at baseline, though these mice exhibit normal 
cardiac function (Gelinas et al., 2008; Luptak et al., 2005). At high work stimulating situations, 
however, these hearts have no energy reserves or ability to process substrates and show 
depressed cardiac function. Interestingly, this was rescued by breeding to a transgenic line that 
overexpresses GLUT1, which can provide sources of glucose and glycogen. Mice with cardiac 
specific ACC deletion (ACC -/-) have, at baseline, a 60% increase in fatty acid oxidation, as 
predicted due to decreased malonyl CoA levels (Kolwicz et al., 2012). These mice also have 
normal cardiac output. After 8 weeks of transverse aortic constriction (TAC), ACC -/- mice are 
comparable to sham control mice, and have normal cardiac function and metabolism. This 
suggests that increased fatty acid oxidation can be protective against pressure overload 
hypertrophy.  
These studies illustrate the power of 13C-tracer studies in Langendorff perfused mouse 
hearts in elucidating the metabolic phenotypes of normal and diseased conditions. We use these 
methods to characterize the metabolic state of mouse hearts in late pregnancy. (Ciulla et al., 
2013)  
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Results 
Cardiac morphometrics and serum metabolites in pregnancy 
After 18 days of pregnancy (late pregnancy, LP) in wild-type, C57/bl6 mice, ratios of the 
heart weight to tibia length increased approximately 13% in the late pregnant mouse (Figure 2.2), 
which confirms the results of previous studies. The heart weight to body weight ratio decreased 
to over 30%, as expected due to increases in body weight during pregnancy (Figure 2.2A). 
Concurrently, a significant increase in total cardiac RNA was observed, while a trend towards 
increased total cardiac DNA is also present (Figure 2.3).  
The extracellular environment of mid (day 12) and late pregnancy (day 18) was 
characterized in non-fasted mice, and of late pregnancy was characterized in non-fasted rats. 
Serum triglycerides in mice increases by mid pregnancy and is sustained through the rest of 
pregnancy (Figure 2.4A). No change in serum glucose is observed in mice (Figure 2.4C) at any 
time points. Interestingly, free fatty acids in the blood is decreased by approximately 50% in late 
pregnancy, but no change is detected in mid pregnancy (Figure 2.4E). There are much more  
  
Figure 2.2: Cardiac hypertrophy occurs in late pregnancy. Timed pregnancy was carried 
out in C57/Bl6 mice at 3 months of age until day 18 of pregnancy (LP), and morphometric 
measurements were taken. Heart weight:body weight (HW:BW, A) and height weight:tibia 
length (HW:TL, B) measurements were made for mice in late pregnancy (n=5) compared to 
non-pregnant controls (n=5). (*p-value < 0.05) 
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dramatic inductions in late pregnant rats. Serum triglycerides increase almost 7-fold, followed by 
an almost 40% reduction in glucose usage (Figure 2.4B and D). We did not evaluate the free 
fatty acid levels in rat pregnancies.  
 
Fatty acid uptake in late pregnancy 
After assessing the physiological milieu of late pregnancy in mice, we characterized the 
fat uptake status. Does more triglycerides in the serum mean there is greater fat import? Previous 
studies in dogs and rats found an increase in fat uptake and utilization in late pregnancy, but 
mouse hearts have not been characterized. In vivo bioluminescence imaging was conducted with  
 
Figure 2.3: Total RNA is increased in late pregnancy. Timed pregnancy was carried out in 
C57/Bl6 mice at 3 months of age until day 18 of pregnancy (LP). (A) RNA and (B) DNA 
were isolated from late pregnant mice (n=5) from 20 mg of heart tissue and non-pregnant 
controls (n=5). Total RNA and DNA were calculated from the total heart weight of each 
mouse. The RNA to DNA ratio was also calculated (D). (*p-value < 0.05) 
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Figure 2.4: Serum metabolite profile in pregnant mice and rats. Serum was collected from 
non-fasted mice and rats at day 12 (MP) and day 18 (LP) of pregnancy, and assayed for 
triglycerides (A and B), glucose (C and D), and free fatty acids (E). (*p-value < 0.05) 
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a transgenic mouse that ubiquitously expresses luciferase (Luc) under the β-actin promoter. 
Anesthetized mice were injected with a probe (FFA-SS-Luc) that links a 16 carbon, nonesterified 
free fatty acid to luciferin. Upon entering the cell, luciferin is liberated from the free fatty acid 
and can then be detected by bioluminescence (Figure 2.5A). Day 18 pregnant Luc mice were 
injected with the FFA-SS-Luc and compared to non-pregnant controls (the same probe 
concentrations were injected in both conditions). There is a 20% increase in fat uptake in late 
pregnant mouse hearts (Figure 2.5E). Hearts were quickly excised from Luc mice and 
bioluminescence imaging was conducted on isolated tissue. A similar increase in fatty acid 
uptake was observed in excised hearts from late pregnant mice (data not shown). Overall, an 
increase in dynamics and saturation of fatty acids in late pregnant mouse hearts is observed.  
 
 Metabolic flux analysis in late pregnancy 
 To determine if the increase in fatty acid uptake parallels utilization, 13C metabolic tracer 
analyses were carried out. In Langendorff perfused systems, the heart is able to work close to 
physiological conditions, and intrinsic properties of the heart 
are assessed without confounding variables. Furthermore, 
ventricular pressure can be continuously measured with a 
fluid-filled balloon inserted into the left ventricle. The heart is 
also paced at 420 beats per minute to ensure continuous 
beating. We began with optimization studies. Wild-type 
C57/bl6 mouse hearts were perfused with a non-circulating 
modified Krebs-Henseleit Buffer (mKHB, Table 2.1).  
Table 2.1: Langendorff 
perfusion buffer 
components 
118 mM NaCl 
4.8 mM KCl 
2.5 mM CaCl2 
1.2 mM KH2PO4 
1.2 mM MgSO4 
25 mM NaHCO3 
0.1 mM EDTA 
50 µM L-carnitine 
5 mM Glucose 
0.4 mM Palmitic acid 
1.5 mM Lactate 
0.2 mM Pyruvate 
0.5 mM Glutamine 
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Figure 2.5: Increased fatty acid uptake in late pregnant mouse hearts. Mice with whole 
body luciferase expression were set up to day 18 of pregnancy. (A) A FFA-luciferin probe was 
intravenously injected in non-pregnant and late pregnant mice. Once inside the cell, 
glutathione (GSH) cleaves the probe to liberate luciferin, which can then be converted to 
oxyluciferin and a photon of light by luciferase. Quantification of photon flux in 
bioluminescence imaging can then be conducted to assess fatty acid uptake. (B) HW:TL ratios 
are shown for the quantified mouse sets. (C) Bioluminescence images were taken at various 
time points up to 7.51 minutes, with late pregnant (right) and control (left) mice. The region 
of interest (ROI) is circled in red and corresponds to the location of the heart. (D) Dynamics 
of uptake for the representative set in (B) are plotted over time, and overall total flux at the 
time of saturation around 6-7 minutes was plotted for 7 late pregnant mouse sets (E). (Ctrl 
(n=7), LP (n=6), *p-value < 0.05) 
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Figure 2.5 (continued) 
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Contents of this buffer were chosen from previously published papers (Khairallah et al., 2004). 
In short, components of the buffer were selected so as to be as close to physiological conditions 
as possible. Hearts were equilibrated first for 20 minutes with unlabeled buffer. Then, the 
perfusate was switched to either no labeled substrates, 13C-glucose, 13C-palmitic acid, or 13C-
glutamine mKHB for 25 minutes (all 13C-substrates were uniformly labeled). We found that 
glutamine was not a utilized substrate for heart tissue, as there was very little incorporation of 
13C with labeled glutamine perfusion (data not shown), so the results presented here will include 
only hearts perfused with 13C-glucose and 13C-palmitic acid. We detected incorporation of 13C in 
the intermediates of glycolysis and TCA after perfusion with 13C-glucose and 13C-palmitic acid 
(Figure 2.6A). The greater abundance of labeled TCA metabolites from 13C-palmitic acid 
compared to 13C-glucose is due to the presence of physiological levels of unlabeled pyruvate and 
lactate, which dilutes out labeling with 13C-glucose. Furthermore, perfusion with 13C-glucose for 
45 minutes yielded increased labeled isotopomer species for TCA intermediates (Figure 2.6B). 
We concluded that 25 minutes of perfusion with labeled substrates is sufficient to detect labeled 
downstream intermediates.  
Next, late pregnant mouse hearts were perfused for 25 minutes with 13C-glucose or 13C 
palmitic acid. We found that late pregnant mouse hearts utilize approximately 30-50% less 
glucose than their non-pregnant counterparts by comparing the labeled isotopomer species of 
TCA intermediates in late pregnant mouse hearts perfused with 13C-glucose to non-pregnant 
controls perfused with 13C-glucose, as shown in Figure 2.7A. Conversely, pregnant mouse hearts 
perfused with 13C-palmitic acid showed an approximately 20% increase in fat usage, compared 
to non-pregnant controls perfused with 13C-palmitic acid (Figure 2.7A). To summarize this more 
clearly, we combined each labeled isotopomer species for a given metabolite in 13C-glucose and  
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Figure 2.6: Incorporation of labeled carbons into glycolysis and TCA. (A) Wild-type, 
C57/bl6 hearts were perfused with unlabeled, 13C-glucose or 13C-palmitic acid modified KHB 
buffer for 25 minutes after equilibration with label-free media. Then, metabolites were 
extracted and samples were processed by mass spectrometry. Metabolites from glycolysis and 
the tricarboxylic acid (TCA) are plotted in the above graph. (Ctrl n=2; 13C-glucose n=2; 13C-
PA n=4). (B) Wild-type, C57/bl6 hearts were perfused with unlabeled or 13C-glucose 
modified KHB buffer for 45 minutes or 25 minutes after equilibration with label-free media. 
Then, metabolites were extracted and samples were processed by mass spectrometry.  (Ctrl 
n=2; 13C-glucose 45 minute n=3, 25 minute n=2). 
56 
 
 
 
  
Figure 2.6 (Continued) 
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  Figure 2.6 (Continued) 
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13C-palmitic acid perfused hearts and compared late pregnancy to non-pregnant (Figure 2.7B and 
C). This observation is consistent among all the metabolites observed here of the TCA and 
confirms the general decrease in glucose utilization and increase in fatty acid utilization from 
other pregnant animals.  
In an attempt to tease out metabolic flux specifically in cardiac cells, we isolated mouse 
adult cardiomyocytes and then incubated cells with labeled 13C-glucose for 30 minutes. Adult 
cardiomyocytes are extremely sensitive to isolation, and if not carefully maintained, can overload 
with calcium and hypercontract to death. Thus, treatment of cells with an inhibitor of 
contraction, 2,3-butanedione 2-monoxime (BDM), in the labeling solution is necessary. 
However, this environment creates quiescent cells, and could greatly compromise their metabolic 
capacity. Figure 2.8 shows that 80-90% of each glycolytic intermediates, including glucose-6-
phosphate and 3-phosphoglycerate, are labeled, suggesting saturation of glycolysis. However, 
very little incorporation of labeled glucose is exhibited in downstream TCA intermediates. In 
fact, the incorporation is predominantly anaplerotic due to the presence of the m3 isotopomer in 
oxaloacetate, fumarate, and malate, but the lack of the same species in succinate and α-
ketoglutarate. We concluded that the limitations in labeling isolated cardiomyocytes would not 
allow us to assess the true metabolic phenotype of late pregnancy.  
 
 
 
Discussion 
We show here that in late pregnancy, there is an increase in serum triglyceride levels and 
an increase in uptake of fatty acids into mouse hearts. Furthermore, this increase in import 
parallels an increase in fat usage and a decrease in glucose usage. Previous reports have shown 
decreased glucose utilization and increased fat utilization in rats and dogs, but no mechanisms  
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Figure 2.7: Lower glucose utilization in late pregnant mouse hearts. Late pregnant (day 
18) and non-pregnant (Ctrl) mouse hearts were perfused with 13C-glucose (blue) or 13C-
palmitic acid (red) for 25 minutes after equilibration with label-free media. Then, metabolites 
were extracted and samples were processed by mass spectrometry. Various metabolites from 
glycolysis and the citric acid cycle (TCA) are shown (A). Percent change between non-
pregnant and late pregnant mouse hearts was calculated for the prominently labeled 
isotopomers of the above metabolites from the TCA cycle (B). The percent change of all 
labeled isotopomer species between 13C-glucose for Ctrl and D18, 13C-palmitic acid for Ctrl 
and D18 were calculated for the metabolites of the TCA cycle (C). (13C-glucose n=3; 13C-PA 
n=3; 13C-glucose D18 n=6; 13C-PA D18 n=5, *p-value < 0.05) 
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  Figure 2.7 (Continued) 
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   Figure 2.7 (Continued) 
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  Figure 2.7 (Continued) 
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Figure 2.8: Metabolic flux analysis of isolated adult cardiomyocytes labeled with 13C-
glucose. Cardiomyocytes were isolated from wild-type mice and then incubated with 13C-
glucose for 30 minutes. Metabolites were isolated from the samples and were then analyzed 
by LC-MS.  
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have been proposed. Due to the dearth of studies on maternal cardiac changes during pregnancy 
in mice and the increasing value of using mouse models of diseases, we set out to better 
characterize the metabolic status of late pregnancy in mouse hearts. We used 13C-metabolic flux 
analysis to directly characterize metabolite changes, a perspective that has not yet been studied in 
hearts from pregnant animals. We found that mouse hearts undergo a similar substrate switch in 
late gestation as other species.  
Morphometric changes occur in pregnancy consistent with what was previously shown 
by others (Chung et al., 2012). Heart weight to tibia length increases approximately 10% in late 
pregnancy. Total RNA also increases in late pregnancy, suggesting increased transcription. There 
is no significant change in total DNA, but a trend towards an increase. If DNA is increased, this 
would suggest increased proliferation in late pregnancy, which we have not characterized. One 
group showed that in late pregnant rat hearts, there is no increase in Ki67, a marker of 
proliferation (Ciulla et al., 2013). However, those studies were in rats and it is possible that 
pregnant mouse hearts adapt differently. Furthermore, the ratio of total RNA to total DNA is 
unchanged – this would suggest that there is no cardiac hypertrophy. These results are puzzling, 
but more studies and greater sample sizes would need to be conducted to determine if total DNA 
content is truly upregulated in late pregnant mouse hearts.  
The metabolic serum profiles were also assayed in pregnant rodents. Both mice and rats 
show higher serum triglycerides in late pregnancy, although rats show a much more drastic 
induction than mice do. There is no decrease in serum glucose levels in mouse pregnancies, but 
rats have a decreased, though not significant, serum glucose concentration in late pregnancy. 
Serum glucose levels were determined for non-fasted animals in all cases, but surprisingly, the 
concentrations are extremely low and comparable to fasted animals. This is likely due to a 
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collection artifact, as clotting protocol consisted of room temperature incubations and could have 
resulted in metabolically active red blood cells that took up glucose as a substrate source. Thus, 
measurements of glucose concentrations in plasma may yield more reliable values. We also 
found that rats have a much more drastic metabolic profile at late pregnancy than mice do, which 
is more consistent with what is observed in humans (Table 1.1). We assayed free fatty acids in 
mouse serum, and while there is no change in mid-pregnancy, there is decreased free fatty acid 
levels in late pregnancy. This is an interesting result, and it is unclear what causes increased 
triglyceride levels, but decreased free fatty acids. However, it is possible that increased uptake of 
free fatty acids into the late pregnant heart results in decreased serum concentrations. In humans 
(Table 1.1), an approximately 10% increase in free fatty acids is observed, while there is an 
almost 70% increase in triglycerides by late pregnant. Thus, it is clear that there are limitations of 
using the mouse models of pregnancy, as the serum profile of mouse pregnancies do not exactly 
recapitulate human serum profiles.  
We move from the extracellular environment to the uptake of substrates into cardiac 
tissue. With the luciferase transgenic mouse, we found a 20% increase in fatty acid uptake. This 
is consistent with previously published findings in rats and dogs (Sugden and Holness, 1993a; 
Williams et al., 2008). However, previous studies did not use this in vivo, luciferase model to 
study fatty acid uptake in pregnancy. This model allows real-time uptake measurements, and 
observation of both the dynamics and saturation of fatty acid uptake in mouse hearts (Henkin et 
al., 2012). The heart weight to tibia length measurements do not increase in these mice as before. 
However, this could be confounded by other factors, such as the background of these mice 
(FVB/b6 mixed background compared to C57/bl6), the number of pups that were born in each 
litter (small litter sizes sometimes results in decreased adaptations), or perhaps slight errors in 
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measurements that may blunt small increases. Thus, we conclude that pregnant mouse hearts 
increase fatty acid uptake in late gestation. We also attempted to assay glucose uptake in late 
pregnant mice with 13C-2-deoxyglucose injections, but were unsuccessful due to the technical 
problems. 
Next, we used 13C-tracer analysis to study the metabolic landscape in late pregnant mouse 
hearts. As described above, the new sensitivity of MS has facilitated detection of the isotopomers 
of many TCA and glycolytic intermediates. Pilot studies were conducted to determine optimal 
times of perfusion. We chose to conduct all late pregnancy experiments at 25 minutes of 
perfusion with labeled substrate due to the presence of 13C in TCA intermediates at that time. It 
is worth noting, however, that results from 45 minutes of perfusion with 13C-labeled glucose 
suggests that steady state has not been reached at 25 minutes. Furthermore, the lack of insulin 
and slightly elevated concentrations of lactate likely leads to underestimation of total glucose 
utilization in perfused hearts. In addition, the perfusion buffer also contains unlabeled pyruvate 
and lactate, which significantly dilutes out the contribution of labeled glucose to the TCA cycle. 
This confirms previous papers that pyruvate and lactate both contribute to acetyl CoA formation, 
but also prevents comparison between utilization of glucose and fat in these conditions. Future 
studies with 13C-lactate of Langendorff-perfused hearts would illuminate the importance of 
lactate as an energy source in late pregnancy. Total lactate concentrations in the late pregnant 
mouse heart has also not been determined. If lactate levels are altered, this would be 
accompanied by changing transporter (MCT1 or MCT4) expression. Thus, it is next necessary to 
examine lactate uptake and oxidation pathways to determine its contribution in late pregnancy.   
Late pregnant mouse hearts decline in glucose utilization and increase in fatty acid 
oxidation. This supports earlier findings in rats and dogs. The glucose usage decline is extremely 
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striking, while fatty acid oxidation increases, which while consistently, are not significant and 
not as prominent as glucose. This is the first study, as far as we know, to explore metabolic flux 
in late pregnant mouse hearts. Interestingly, we observed an increase by 20% in fatty acid uptake 
in the luciferase mouse studies, and for some TCA intermediates, similarly see a 20% increase in 
flux through β-oxidation, although the error are quite large for some. Thus, it would be revealing 
to look at total triglyceride content in late pregnant mouse hearts to determine if incoming fatty 
acids are being partitioned to triglyceride synthesis and storage. We attempted to tease out this 
finding in isolated cardiomyocytes, but due to the challenges of culturing these cells, did not 
further pursue this.  
It is also evident from perfusion of 13C-labeled substrates in late pregnant mouse hearts 
that there are intrinsic cardiac adaptations that occur in late pregnancy, independent of substrate 
availability. Both non-pregnant and late pregnant mouse hearts were exposed to the same 
substrate concentrations but consumed them very differently. Thus, it is not merely the presence 
of substrates in late pregnancy that determines what the heart uses but inherent changes in the 
myocardium itself that is determining substrate use. What these are and the factors responsible 
for regulating them will be further explored in Chapter 2.  
Here, we found that in late pregnancy, heart weight and total RNA levels are increased. 
Furthermore, higher serum triglycerides characterize the late gestation environment in mouse and 
rat, although their serum glucose levels are contradictory. Mouse hearts in late pregnancy take up 
more fatty acids and have decreased glycolytic flux but higher fatty acid oxidation. This 
substrate switch is due to an intrinsic cardiac response to the late pregnant state, but it is not yet 
known what is responsible.      
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Materials and Methods 
Animal studies. All animal studies were performed according to procedures approved by the 
Institutional Animal Care and Use Committee (IACUC) at Beth Israel Deaconess Medical Center 
(BIDMC). Mice were maintained on a standard rodent chow diet with 12 hours light and dark 
cycles with water and food ad libitum. Luciferase (Luc, Stock number 008450) and C57/bl6 mice 
were purchased from Jackson Laboratories (Bar Harbor, Maine). Luc mice (FVB background) 
were bred to C57/bl6 females to produce Luc.FVB/b6 mixed background progeny that were used 
for luciferase assays. Wild-type, three-month-old female C57/bl6 and female Luc.FVB/b6 mice 
undergoing estrus were mated with wild-type, C57/bl6 breeder males. The presence of a 
copulatory plug is denoted as day 0 of pregnancy. Pregnant females were singly placed in a new 
cage, and breeder diet (Formulab 5058) replaced the standard chow (Formulab 5008) they were 
previously on, unless delineated differently elsewhere. Breeder diet contains more fat and 
calories compared to standard chow. Timed pregnancies were carried out to day 11-12 (mid-
pregnancy) and day 17-18 (late pregnancy) of gestation. Timed pregnant rats (Sprague Dawley) 
were obtained directly from Charles River.  
Reagents and Materials. Unless otherwise stated, all reagents were from Sigma. 13C-labeled 
substrates were from Cambridge Isotope Laboratories.  
Organ Weight and Hypertrophy Assessment. At day 18 of pregnancy, mice were measured 
for body weight. Hearts were then harvested, rinsed in PBS to remove blood from ventricles, 
dried and weighed. Heart weight, body weight, and tibia length measurements were recorded. 
Hypertrophy was determined by calculating heart weight to body weight (HW/BW) and heart 
weight to tibia length (HW/TL) ratios.  
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DNA and RNA Isolation. Upon harvesting, mice tissues were immediately frozen in liquid 
nitrogen. 20 mg of heart tissue was used for the total RNA studies, and 20 mg for the total DNA 
studies. Total RNA was isolated from mouse tissue with the TRIzol (Invitrogen) and chloroform 
method. Total DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen). RNA and 
DNA concentrations were measured with the ThermoScientific NanoDrop spectrophotometer, 
and total RNA and DNA in the hearts were calculated by normalizing to total heart weight for 
each mouse.  
Serum metabolite assays. Blood was collected from non-fasted mice or rats at mid- or late 
pregnancy via cheek puncture (mid-pregnancy) or terminal cardiac puncture (late pregnancy). 
Coagulation was allowed to occur for 30-45 minutes at room temperature, and then was 
centrifuged for 20 minutes at 2000g to obtain the serum fraction. Serum triglyceride (Cat. No. 
100010303, Cayman, MI), glucose (Cat. No. 10009582 Cayman, MI), and free fatty acids (Cat. 
No. 700310, Cayman, MI) were measured.  
In vivo fatty acid bioluminescence. Bioluminescence studies were conducted at the Longwood 
Small Animal Imaging Facility (SAIF). Two days before imaging, chest hair was removed with a 
topical, depilatory cream. Protocol for injection and uptake was described briefly (Henkin et al., 
2012). Mice were sedated with isoflourane and then intravenously injected (retro-orbital) with 
100µL of 20 µM FFA-luciferin (Intrace Medical). Mice were placed in the supine position in the 
imaging chamber of the Xenogen IVIS-50 Bioluminescence Imaging System (Perkin Elmer). 
After data collection, hearts were removed and quickly imaged to obtain ex vivo uptake 
measurements. Flux analyses were performed and region of interest (ROI) were chosen with the 
Living Image Software from Xenogen. 
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Langendorff perfusion. Non-circulating, Langendorff perfusion was performed as described 
previously (Liao et al., 2001). Briefly, mice were sedated with ketamine and xylazine mixture. 
Hearts were removed and immediately placed in cold saline. Then, a cannula was placed into the 
aorta to undergo perfusion with non-labeled buffer for 20-25 minutes. The modified Krebs-
Henseleit buffer (KHB) used contained 118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 0.1 mM EDTA, 50 µM L-carnitine, 5 mM glucose, 
0.4 mM palmitic acid conjugated to 2% BSA, 1.5 mM lactate, and 0.2 mM pyruvate, with the pH 
adjusted to 7.35. The buffer composition was chosen due to previously published reports 
(Khairallah et al., 2004; Vincent et al., 2004). The buffer was gassed with 95% CO2/5% O2 and 
maintained at 37oC throughout the entirety of the experiment. A small tubing (PE-50) was used 
to pierce through the left ventricles to prevent fluid buildup. A balloon connected to a pressure 
transducer was then inserted into the left ventricle and inflated to measure ventricular function. 
The end-diastolic pressure, which was constant at around 5-10 mmHg, can be controlled by the 
inflation of the balloon. Hearts were paced at 420 beats per minute, and perfusion pressure was 
set at 80 mmHg for the whole study. After stable perfusion for 20 minutes, perfusate was 
switched to labeled substrates for 25 minutes.  
Tissue preparations for mass spectrometry. After 25 minutes of labeling, the heart was 
immediately freeze clamped with tongs pre-chilled in liquid nitrogen. The tissue was pulverized 
with mortar and pestle, and the weight recorded. Metabolites were extracted with 80% methanol 
in H2O with 0.1% formic acid. For the second and third extractions, a 40:40:20 ratio of 
methanol: acetonitrile: H2O solution was used. All three extractions steps were completed with 
centrifugations at maximum speed for 5 minutes at 4oC. Then, the samples were dried under 
nitrogen gas before processing by mass spectrometry.  
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Isolated adult cardiomyocytes from mouse hearts. Adult mouse hearts were excised and 
perfused via Langendorff perfusion, first with perfusion buffer (137 mM NaCl, 4 mM KCl, 1 
mM MgCl2, 10 mM HEPES, 0.33 mM NaH2PO4, 10mM glucose, 5 mM taurine, and 10 mM 
BDM), before switching to an enzyme buffer with collagenase D (Roche), collagenase B 
(Roche), and protease XIV for 10-15 minutes. Calcium was reloaded with concentrations of 0.06 
mM, 0.25 mM, 0.60 mM, and 1.2 mM. Adult cardiomyocytes were plated on laminin-coated 
tissue culture plates for 2 hours in MEM (Invitrogen), 10% calf serum, BDM, 2mM glutamine, 
and 2mM ATP before switching to labeled media.  
Labeled media treatment of cardiomyocytes and preparation for mass spectrometry. Adult 
cardiomyocytes were treated for 30 minutes with 13C-labeled substrates in modified KHB buffer 
as described above. Then the cells were washed quickly in PBS twice and incubated with pre-
chilled 80% methanol solution. After two more extractions with centrifugations at the highest 
speed for 10 minutes, nitrogen gas was used to dry the samples.  
Measurement of 13C-labeling pattern of cellular metabolites using liquid chromatography 
mass spectrometry (LC-MS). Samples were sent to the Metabolomics Core at the Penn 
Diabetes Research Center (DRC) for further processing. In brief, samples were resuspended in 
100µL HPLC-grade water (for each well of a 6-well plate) or 1000µL HPLC-grade water for 
40mg of heart tissue. Samples were analyzed via reverse phase ion-pairing chromatography 
coupled to an Exactive orbitrap mass spectrometer (ThermoFisher Scientific, San Jose, CA).  
The mass spectrometer was operated in negative ion mode with a scan rate of 1 Hz and resolving 
power of 100,000, scanning range being m/z 75-1000. The LC method has been described before 
(Lu et al., 2010), using a Synergy Hydro-RP column (100 mm × 2 mm, 2.5 μm particle size, 
Phenomenex, Torrance, CA) with a flow rate of 200 μL/min. The LC gradient was 0 min, 0% B; 
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2.5 min, 0% B; 5 min, 20% B; 7.5 min, 20% B; 13 min, 55% B; 15.5 min, 95% B; 18.5 min, 
95% B; 19 min, 0% B; 25 min, 0% B. Solvent A is 97:3 water−methanol with 10 mM 
tributylamine and 15 mM acetic acid; solvent B is methanol.  Other LC parameters were 
autosampler temperature 5°C, injection volume 10 μL, and column temperature 25 °C. The data 
analyses were performed using MAVEN software (Melamud et al., 2010). The metabolites, both 
unlabeled and the 13C-labeled forms, were detected using the accurate mass with a 10 ppm m/z 
window. Data were corrected to remove the contribution from the nature isotope 13C as described 
before (Munger et al., 2008). Labeling percentages were calculated from signal intensity using 
Excel.  
 
Fractional abundance was calculated with the following equation:  
Fractional Abundance of each isotopomer = 
𝑚(0,1…𝑛)
𝑚0+𝑚1+⋯+𝑚𝑛
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Regulations of substrate switch in late pregnancy 
 
 
 
 
 
 
 
 
 
 
Attributions: Laura Liu performed all experiments for this section unless otherwise noted. Dr. 
Glenn C. Rowe isolated mitochondria and performed the seahorse experiments. Dr. Barbara 
Kahn and Dr. Jack Lawler kindly provided the GLUT4 and CD36 deleted mouse tissues. Dr. 
Adam Wende generously donated the PDK4 KO mouse hearts, and Dr. Robert Harris provided 
the PDK4 antibody.   
77 
 
Abstract 
Maternal cardiac metabolism defers to fetal preference for glucose by decreasing glucose 
consumption and increasing fatty acid oxidation. The factors responsible for this switch in late 
pregnancy has not been found. We determine here that mitochondrial biology is unchanged at the 
end of gestation. Furthermore, there are no alterations in the expression of enzymes in the 
triglyceride synthesis or turnover pathways or in the expression and localization of substrate 
transporters. Interestingly, we observed a muscle-specific induction of pyruvate dehydrogenase 4 
(PDK4). PDK4 can regulate entry of pyruvate into the TCA cycle by phosphorylation of 
pyruvate dehydrogenase (PDH) and is crucial for connecting glycolysis, β-oxidation, and the 
TCA cycle. Furthermore, we found that treatment of isolated cardiomyocytes with the pregnancy 
hormone progesterone results in upregulation of PDK4. Mifepristone, an antagonist for the 
progesterone receptor, reverses this effect. Taken together, these studies point to PDK4 as a 
potential regulator of substrate switch in late pregnant mouse hearts.  
 
Introduction 
Fetal demands supersede maternal substrate usage during pregnancy. Late gestation is a 
state of insulin resistance and hyperlipidemia in the mother. The myocardium complies by 
decreasing glucose utilization and increasing fatty acid uptake and usage (Chapter 1). But what 
regulates this substrate switch? Metabolic pathways are regulated at many different points, 
including substrate availability, transporter localization, allosteric control of crucial enzymes, 
transcriptional control, post-translational modifications, and many more. What occurs during 
pregnancy has not been fully explored.   
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In this chapter, we seek to determine the regulator of substrate switch in late pregnancy. 
We will explore mitochondrial content and function, glucose transporter localization, and 
pyruvate dehydrogenase (PDH) regulation. Determining what controls substrate consumption in 
normal pregnancy will facilitate our understanding of whether cardiac diseases of pregnancy 
result from vulnerabilities in regulation. 
 
Mitochondria in the heart 
Over 95% of the ATP generated in the heart is derived from oxidative phosphorylation in 
the mitochondria, underscoring the importance of this organelle in fulfilling tissue energetic 
needs (Kolwicz et al., 2013). Disruption of mitochondrial processes, such as biogenesis, genome 
replication, or dynamics, can lead to diseased states. In fact, a hallmark of heart failure in 
humans and rodents is a decrease in mitochondrial copy number and content that is correlated 
with cardiac dysfunction (Bayeva et al., 2013). Certain physiological stimuli, such as exercise, 
can protect against age-related declines in mitochondria by promoting mitochondrial biogenesis 
(Holloszy and Booth, 1976). Thus, exploring the mitochondrial state of late pregnancy, 
especially with observed changes in substrate availability, will elucidate if adaptations have been 
made to this vital organelle.  
Mitochondria have simple beginnings. Once a bacteria cell that was likely engulfed by a 
neighboring eukaryotic cell, they have evolved to become one of the most critical components of 
their host cell. It is an endo-symbiotic relationship, one in which over time the bacteria has lost 
its abilities to survive without its host, relying on it to transcribe and translate the majority of its 
genome (only 13 mitochondrial proteins are made in the mitochondria), and the host has become 
dependent on the ATP generated by its guest (relying on it for over 95% of its needs).  
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Cardiac mitochondria is different than that of other tissues (Song and Dorn, 2015). In 
most cells, mitochondria are dynamic, continuous, and form network structures. Elongation 
(“fusion”) or fragmentation (“fission”) is constantly occurring, depending on the needs of the 
cell. In the heart, however, mitochondria are completely different – they are short, small, 
fragmented and static. Fusion or fission seldom occur, and it takes over two weeks to complete a 
cycle (Beraud et al., 2009; Chen et al., 2011). This design is deliberate, it seems, as cardiac 
contractions would require tissue malleability, and long networks of mitochondria would hinder 
this. Though their phenotype differs from other cells types, fusion and fission do seem to have an 
important role as cardiac-specific ablation of genes involved in these processes can lead to 
cardiac dysfunction, respiratory abnormality, and cardiomyopathy (Chen et al., 2012a; Chen et 
al., 2012b; Chen et al., 2011; Kasahara et al., 2013; Papanicolaou et al., 2012a; Papanicolaou et 
al., 2012b; Song et al., 2015).  
The metabolic pathways in the mitochondria are crucial to providing energy to the tissue 
(Stanley et al., 2005). β-oxidation, the tricarboxylic acid (TCA) cycle, and the electron transport 
chain (ETC) all reside in different parts of the mitochondria. The membrane duality of this 
organelle, with an inner mitochondrial membrane (IMM), surrounded by an outer mitochondrial 
membrane (OMM), is specifically created to facilitate these processes. β-oxidation and the TCA 
cycle occur in the mitochondrial matrix, the space inside the IMM. ETC complexes are on the 
IMM, and the proton gradient they create is in the space between the IMM and the OMM, 
entitled the intermembrane space (IMS). This double barrier also protects against any deleterious 
byproducts created from these metabolic pathways.  
Since the principal function of the mitochondria is to provide ATP by oxidative 
phosphorylation, one way to assess mitochondrial capacity is by oxygen consumption in the 
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ETC. The ETC is made up of four complexes, each with the ultimate goal of pumping proteins 
from the matrix into the IMS to produce a proton gradient (Figure 3.1A). The driving force for 
electron transfer through the ETC is the free energy associated with reduction of oxygen to 
water. NADH and FADH2 created from the TCA cycle, donate electrons to NADH-Q 
oxidoreductase (Complex I) and Q-cytochrome c oxidoreductase (Complex II), respectively. 
NADH donates two electrons to Complex I, which results in four protons transferred to the IMS. 
Complex II, on the other hand, contains succinate dehydrogenase, an enzyme in the TCA cycle 
that converts succinate to fumarate to generate FADH2. Donation of electrons from FADH2 does 
not contribute to formation of the proton gradient. Electrons from both complexes, traveling via 
electron carriers, arrive at Q-cytochrome c oxidoreductase (Complex III), where they are 
transferred to another carrier, cytochrome c. In this process, another four protons are transported 
to the IMS from the matrix. The fourth complex, cytochrome c oxidase, transfers electrons to 
reduce oxygen to water. The highly favorable reduction of oxygen drives the formation of the 
proton gradient, which is then used to drive ATP generation by the ATP synthase (Complex V), 
which is energetically unfavorable.  
One common method to study mitochondrial respiration function is with inhibitors for the 
different complexes of the ETC on isolated mitochondria, concurrently with measurement of the 
oxygen consumption rate (Figure 3.1B). Doing so will allow targeting of dysfunction on the 
respiration of specific complexes (Readnower et al., 2012). We use this technique to assess 
mitochondrial respiration in isolated mitochondria from late pregnant hearts. Common inhibitors 
utilized include rotenone (complex I inhibitor), antimycin A (complex III inhibitor), and 
oligomycin (complex V inhibitor). First, basal respiration is assessed with ADP and energy  
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Figure 3.1: ETC and mitochondrial respiration. (A) The electrons donated from the 
products of the TCA cycle, NADH and FADH2, first travel to complex I and complex II of 
the ETC. The transfer of electrons through the ETC is coupled to the formation of the proton 
gradient in the IMS, and is driven by the free energy associated with the reduction of oxygen 
to water. Ultimately, this proton gradient drives the production of ATP by ATP synthase. (B) 
Oxygen consumption rate (OCR) is often used as a measure of mitochondrial functional 
capacity. Treatment of isolated mitochondria with inhibitors for the complexes of the ETC can 
be used to measure respiration under different conditions. First, in the presence of ADP and 
substrates, basal respiration is measured. Then, oligomycin, a complex V inhibitor, is added, 
leading to decreased respiration that is due to ATP production. Then, mitochondria are treated 
with FCCP, an uncoupler that will dissipate the proton gradient to lead to uninhibited electron 
transporter through the ETC and maximal oxygen consumption. Finally, antimycin A, a 
complex III inhibitor, shuts down respiration.  
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substrates. Then, mitochondria are treated with oligomyocin, which results in a decrease in the 
respiration due to ATP production. Next, uncouplers (FCCP, DNP), which completely dissipate 
the protein gradient to allow uninhibited electron transfer through the ETC, are used to determine 
maximal respiration status. Finally, antimycin A is added to fully shut down mitochondrial 
respiration (Figure 3.1B). Many groups have used this method to characterize cardiac 
mitochondria during heart failure (Nojiri et al., 2006; Sharov et al., 1998). While there have been 
some discrepancies, for the most part, decompensated heart failure is accompanied by 
impairments in complex I respiration (Rosca et al., 2013).  
Alterations to mitochondrial capacity, copy number, biogenesis, and respiration are made 
in many physiological processes, such as heart failure or exercise (Doenst et al., 2010; 
Karamanlidis et al., 2011). Little has been studied about mitochondrial adaptations in the heart 
during pregnancy. One group found no difference in mitochondrial morphology with confocal 
microscopy studies (Bassien-Capsa et al., 2006). However, the increased workload of late 
pregnancy indicates that increased ATP demand could be accompanied by adaptations of the 
mitochondria to provide for this greater need.  
 
Regulating substrate switch with transporter localization 
Though substrate availability is a key determinant of usage in the heart, the import of 
substrates into the cell is still a highly regulated process (Schwenk et al., 2008). Two types of 
transporters are thought to be responsible for the majority of glucose and fat uptake, GLUTs (of 
which GLUT1 and GLUT4 are the most highly expressed in the heart) and CD36. Mice with 
deletion in cardiac CD36 decrease fatty acid uptake by approximately 70% and treatment of cells 
with an inhibitor of CD36, sulfo-N-succinimydyl-oleate (SSO), completely ablated fatty acid 
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uptake (Coburn et al., 2000; Coort et al., 2002; Habets et al., 2007). Furthermore, cardiac 
specific GLUT4 mice lack any insulin-stimulated glucose uptake, though their basal glucose 
uptake levels are normal, due to compensation by GLUT1 (Abel et al., 1999). There are 
similarities and differences in their regulation – both translocate when activated, and both 
respond to contraction and insulin. But they have very different means of storage and 
downstream effects. Assessing the expression and location of these transporters in late pregnant 
mouse hearts in the triglyceride-rich environment of late pregnancy can shed light on the role of 
CD36 and GLUT4 in substrate switch. 
GLUT4 and CD36 have been well characterized to reside in intracellular vesicles until a 
stimulus induces their translocation to the sarcolemmal membrane (Steinbusch et al., 2011). 
There are two intracellular pools of GLUT4 – an endosomal pool and a non-endosomal pool that 
respond to different stimuli (Slot et al., 1991). Only 50% of CD36 transporters, on the other 
hand, are intracellular, while the majority of GLUT4 is intracellular until needed (Fischer et al., 
1997; Luiken et al., 2004b; Luiken et al., 2002b). Furthermore, GLUT4 and CD36 occupy 
distinct subdomains of the sarcolemma – CD36 is thought to be in lipid raft-rich caveolae and 
GLUT4 has been characterized in caveolae and outside. 
Though insulin and contraction can activate cellular localization of both transporters, 
their end goals are very different. Insulin signals for storage of substrates, whereas contraction 
promotes oxidation to generate ATP. Thus, different proteins respond to insulin and contraction. 
When insulin is secreted from pancreatic β-cells in response to feeding, it binds to insulin 
receptors on cardiomyocytes, which results in the phosphorylation of insulin receptor substrates 
1 and 2 (IRS1/2) (Boucher et al., 2014). IRS1 activates the p85 regulatory component of 
phosphatidylinositol-3-phosphate (PI3K) (Luiken et al., 2002b). PI3K generates PI-3,4,5-
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triphosphate (PIP3), which is responsible for inducing multiple kinases, including Akt/PKB and 
protein kinase C (PKC). These kinases directly inhibit AS160 (Akt substrate 160) to activate the 
rab GTPases that then promote GLUT4 and CD36 vesicle fission, transport, and finally fusion 
with the plasma membrane (Chen et al., 2008; Kramer et al., 2006a; Kramer et al., 2006b; 
Miinea et al., 2005; Roach et al., 2007).  
On the other hand, increased contractile activity in cardiomyocytes signals an increased 
need for ATP (Luiken et al., 2004a). In this state, elevated levels of AMP, cAMP, and reactive 
oxygen species (ROS) work in concert to induce AMP-activated protein kinase (AMPK), protein 
kinase A (PKA), protein kinase D (PKD), and others (Zaha and Young, 2012). AMP can bind the 
regulatory γ-subunit of AMPK, exposing its catalytic α2-subunit to be phosphorylated by LKB1 
(Jorgensen et al., 2004). Activated AMPK has many downstream actions, including increasing 
fatty acid oxidation. Furthermore, AMPK phosphorylates and inhibits AS160 in addition to 
activating the rab GTPases responsible for CD36 and GLUT4 vesicle translocation (Chen et al., 
2008; Yang and Holman, 2005).  
Diseased states show dysregulation of glucose and fatty acid utilization, and transporter 
location is similarly affected. For example, in diabetic cardiomyopathies, the increased presence 
of CD36 on the plasma membrane results in greater influx of fatty acids and ultimately 
lipotoxicity (Coort et al., 2004a; Coort et al., 2004c; Ouwens et al., 2007). Blocking CD36 with 
SSO in obese rats prevents buildup of excess lipids (Coort et al., 2004a). Skeletal muscle 
biopsies from humans with type 2 diabetes also have increased CD36 levels at the plasma 
membrane (Bonen et al., 2004). This parallels the increase in triglyceride levels in these patients. 
Ischemia/reperfusion (IR) also causes a substrate switch to increased glucose consumption that 
affect transporter localization. Rat hearts that underwent IR show 90% increased GLUT4 plasma 
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membrane levels during ischemia and 32% decrease in CD36 plasma membrane concentrations 
(Heather et al., 2013).   
 
Triglyceride synthesis, storage and breakdown in the heart 
The serum triglyceride environment of late pregnancy suggests that synthesis, storage, or 
breakdown of intracellular triglycerides could be altered to adequately meet energetic needs. 
How these pathways play in pregnant hearts have not been explored. 
Upon uptake into cardiomyocytes, fats are activated to fatty acyl CoAs by long chain 
fatty acyl CoA synthetase (FACS). They then have two main fates: to continue on to β-oxidation 
or storage into triglycerides. In the healthy heart, the triglyceride pool has rapid turnover and 
thus is relatively limited. However, conditions where fatty acid oxidation is insufficient to keep 
up with increased fatty acid availability and uptake, such as diabetes, lead to increased 
triglyceride synthesis and lipid droplet formation. While this may be initially beneficial to keep 
harmful lipid intermediates away from the rest of the cell, long-term increases has been shown to 
adversely affect cardiac function. Thus, in the pregnancy state, could elevated serum 
triglycerides affect intracellular storage in the cell? We will explore expression of key proteins 
involved in these pathways in late pregnant mouse hearts.  
The details of triglyceride synthesis and breakdown are explained in many excellent 
comprehensive reviews, so we will focus on the general principles here (Brindley et al., 2010; 
Kienesberger et al., 2013). Fats that enter the cell complete the Kennedy pathway to form 
triglycerides (Figure 3.2). This is dependent on a series of acylations and phosphorylations by 
many families of enzymes located near the mitochondria and the sarcoplasmic reticulum (SR). 
Proximity to these organelles allows rapid hydrolysis and usage when necessary. The enzymes in  
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Figure 3.2: Triglyceride synthesis (Kennedy) and turnover pathways. Activated fatty acyl 
CoAs have two fates: to be oxidized in the mitochondria or undergo triglyceride synthesis by 
a series of enzymes located on the ER/SR surface. This includes a series of acylation and 
phosphorylation events by GPATs, AGPATs, lipins, and DGATs that ultimately results in the 
formation of triacylglycerols (TAG, triglycerides). When necessary, these TAGs can then be 
broken down in sequential hydrolysis reactions by ATGL, HSL, and MAG lipase to create 
glycerol and fatty acids.  
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the Kennedy pathway include glycerol-3-phosphate acyltransferases (GPATs), which catalyze 
the first step of esterification of fatty acids and glycerol-3-phosphate to form lysophosphatidic 
acid (LPA). A second esterification reaction by acylglycerol-3-phosphate acyltransferases 
(AGPATs) produces phosphatidic acid (PA), which is then converted to diacylglycerol (DAG) 
by lipins. The ultimate step is the formation of triglycerides by DAG acyltransferases (DGATs). 
Many of these proteins have been shown to be upregulated under physiological conditions that 
induce triglyceride formation. For example, GPATs levels are increased after fasting, in 
exercise-trained mice and in models of lipotoxic cardiomyopathy (Finck et al., 2002; Liu et al., 
2009; Schoonderwoerd et al., 1990).  
The myocardium is also capable of secreting lipoproteins by the actions of apolipoprotein 
B (apoB) and microsomal triglyceride transfer protein (MTTP) (Boren et al., 1998; Nielsen et al., 
1998). After being made in the SR, lipoproteins are then processed through the trans-Golgi 
network for secretion. Consistent with their known roles, overexpression of apoB leads to 
elevated secretion and increased mtp expression is observed in diabetic states (Bartels et al., 
2009; Nielsen et al., 2002).  
The breakdown of triglycerides from lipid droplets occurs through a series of hydrolysis 
reactions (Figure 3.2). ATGL is the first enzyme to produce DAG through hydrolysis of TAG. 
Due to its rate-limiting role, it undergoes heavy regulation by many factors, including AMPK 
and periplipin-5. The hydrolysis of DAG by hormone-sensitive lipase (HSL) is then followed by 
the final hydrolysis of monoacylglycerol (MAG) lipase to form glycerol and fatty acids. The 
activity and expression of enzymes involved in triglyceride synthesis sand breakdown in hearts 
from late pregnant animals has not been examined. 
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Regulation of PDH by PDKs and PDPs 
In late pregnant mouse hearts, there is a 50% decline in glucose utilization (Chapter 1). 
There are many regulatory points that result in decreased glucose flux. One of them is in the key 
enzyme complex that connects glycolysis to the TCA cycle - pyruvate dehydrogenase complex 
(PDC), which decarboxylates pyruvate to acetyl CoA (Figure 3.3). PDH is one of the 
components of the complex, also named E1 (Holness and Sugden, 2003; Zhang et al., 2014). 
PDH is located in the mitochondria and is strongly regulated by a family of kinases, pyruvate 
dehydrogenase kinases (PDKs), and a family of phosphatases, pyruvate dehydrogenase 
phosphatases (PDPs) (Holness and Sugden, 2003). There are four members of the PDK family, 
of which PDK2 and PDK4 have the highest expression in the heart. There are three serine sites 
(site 1: ser293; site 2: ser300; site3: ser232) on PDH that can be phosphorylated by PDK1-4, 
which have preferential activity towards each site. For example, PDK4 phosphorylates serine site 
2 more so than others, while PDK1 is the only member that phosphorylates site 3. There are two 
members of the PDP family (PDP1-2), of which PDP2 has the greatest cardiac expression.  
Regulation of PDH by PDK affords the cell metabolic flexibility in the face of different 
physiological conditions. For example, states of starvation, obesity, exercise, insulin resistance 
and diabetes all induce PDK4 in muscle (Holness et al., 2002; Lee, 2014; Pilegaard and Neufer, 
2004). Induction of PDK4 inhibits PDH and prevents glucose utilization, while increasing fatty 
acid oxidation. In the case of starvation, this is to save the limited resources and convert to using 
fat as a substrate source. Thus, 48 hour fasted rats exhibit upregulation of PDK4 (Holness et al., 
2002). PDK4-null mice that have been fasted have lower fatty acid oxidation and higher glucose 
use with decreased blood glucose and greater PDH activity (Jeoung and Harris, 2008).  In times 
of excess energy supply, as in obesity and diabetes, however, PDK4 is also upregulated. Both 
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rats fed high fat diets and human type 2 diabetic patients induce PDK4 in skeletal muscle 
(Holness et al., 2000; Hwang et al., 2009; Kulkarni et al., 2012). In PDK4-deleted mice, high fat 
diet for 32 weeks protected against a pathological phenotype – mice have less fat accumulation 
and better glucose tolerance (Hwang et al., 2009). Thus, PDK4 has been at the center of 
therapeutics to increase metabolic flexibility during diseased states.  
PDK4 itself is also regulated by many factors (Figure 3.3). In states of starvation, the  
  
Figure 3.3: Regulation of PDH activity by PDKs and PDPs. PDH is responsible for 
decarboxylation of pyruvate to acetyl CoA. It is tightly regulated by families of PDKs 
(inhibition) and PDPs (activation), which themselves are highly regulated. PDKs are activated 
by states of starvation, diabetes, ischemia, and exercise. The environment is one of high acetyl 
CoA, NADH, and ATP. Many transcription factors and co-activators can induce its expression, 
including PPARs, PGC-1α, FOXO1, and ERRα. Furthermore, it is inhibited by fed states and 
insulin. Pyruvate, NAD+, and ADP can inhibit PDK.  
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high acetyl CoA to CoA and NADH to NAD+ ratios from fatty acid oxidation stimulate PDK4. 
In contrast, pyruvate inhibits PDK4. With less acetyl CoA conversion from pyruvate, less 
malonyl CoA is formed, lifting inhibition on fatty acid oxidation. Forkhead box O1 (FOXO1) 
and FOXO3 are transcription factors that also promote fatty acid utilization and PDK4 
expression (Battiprolu et al., 2012). FOXO1 and PDK4 are both downstream of PPARδ/β. Thus, 
the influx of fats activate PPARδ/β signaling and shifts the transcriptional profile of the cell 
towards fatty acid usage. PGC-1α and ERRα also cooperatively induce PDK4 expression in 
response to exercise stimulation (Wende et al., 2005). Hormones can also affect PDK4 
expression. Insulin, for example, strongly inhibits PDK4 in gastrocnemius muscle (Kim et al., 
2006). Glucocorticoid receptors, on the other hand, can directly bind to the PDK4 promoter to 
stimulate expression (Connaughton et al., 2010).  
There have also been studies in ovariectomized rats implanted with slow release 
progesterone or estrogen tablets that show increased PDK4 expression in skeletal muscle, 
suggesting that hormones of pregnancy can also affect substrate use in pregnant rodents as well 
(Campbell et al., 2003). Interestingly, two groups explored metabolism in pregnancy found no 
change in PDH activity or PDK4 expression in day 18 pregnant rat hearts (Nieuwenhuizen et al., 
1998; Rimbaud et al., 2009), while decreased PDH expression was observed in dogs (Williams et 
al., 2008). However, the role of PDK4 in late pregnancy in mouse hearts is not clear.  
 
Conclusion 
Decreased glucose utilization in late pregnancy implicates alterations in metabolic 
regulation. However, whether the point of control is at mitochondrial phenotype, transporter 
translocation, triglyceride storage, pyruvate entry to the TCA cycle, or others has not been 
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explored. We seek to determine if late pregnant mouse hearts show differences in regulatory 
points compared to non-pregnant mice. Knowledge of this could point to new therapeutic 
perspectives to treat cardiac diseases of pregnancy.  
 
Results 
Normal mitochondrial phenotype in late pregnancy in mice 
To determine if the substrate switch observed in late pregnancy is due to changes in 
mitochondria, we assessed the state of the mitochondria during late pregnancy. Mitochondrial 
DNA copy number (ratio of mito DNA to genomic DNA) is not different between late pregnancy 
and control (Figure 3.4A). Similarly, there is no change in gene expression of nuclear-encoded 
mitochondrial genes or in the expression of the proteins subunits in complexes of the ETC 
(Figure 3.4B and C). Mitochondrial morphology was assessed with mitotracker red staining, and 
no dramatic differences are apparent between late pregnant mouse hearts and non-pregnant 
controls (Figure 3.4D). However, electron microscopy (EM), the gold standard for assessing 
mitochondrial morphology was not performed and may better elucidate more subtle changes. 
Overall, this indicates that in late pregnancy, there are no dramatic changes in the number or 
morphology of cardiac mitochondria.  
We further assayed if mitochondrial dynamics could be altered by examining gene 
expression of proteins involved in fusion and fission. No differences in the expression of 
mitochondrial fusion (Mfn1, Mfn2, Opa1) or fission (Drp1) was observed (Figure 3.5). 
Interestingly, PINK1 (PTEN-induced putative kinase 1), a quality control kinase that targets 
damaged mitochondria for degradation through mitophagy, is significantly decreased by 
approximately 25%. Furthermore, we observed a trend towards decreased expression of Parkin, 
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the E3 ubiquitin ligase that is recruited by PINK1 to the mitochondria, in late pregnant mouse 
hearts. Thus, this suggests that there is potentially decreased mitophagy in late pregnancy, while 
mitochondrial fission and fusion are not changed. However, further studies are necessary to 
confirm that mitophagy is indeed affected.  
Though mitochondrial number is the same, mitochondrial function could still be altered. 
We performed oxygen consumption studies on isolated mitochondria of late pregnant mouse and 
Figure 3.4: Mitochondrial DNA copy number, expression of oxidative phosphorylation 
proteins and morphology are unchanged in late pregnant mouse hearts. (A) DNA was 
isolated from mouse hearts and the ratio of mtDNA to gDNA was calculated for control 
(n=3) and late pregnant mouse hearts (n=3). (B) mRNA was isolated from mouse hearts, 
followed by qRT-PCR to assess expression of nuclear-encoded mitochondrial genes. (C) 
Western blot analysis of proteins subunits of ETC complexes from isolated mitochondria 
from late pregnant and control mouse hearts. (D) Mitochondrial morphology was examined 
by staining with mitotracker red on OCT frozen sections of hearts from late pregnant and 
control mice.  
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rat hearts, compared to non-pregnant control. Respiratory capacity does not change in late 
pregnancy, regardless of the conditions chosen (Figure 3.6). There is no difference in complex I 
or complex II respiration in rats. Furthermore, the choice of substrate (either pyruvate/malate or 
palmitoylcarnitine/malate) does not significantly affect the oxygen consumption rate in mice. It 
is worth noting that a trend towards decreased basal and maximal respiration is observed in late 
pregnant mouse hearts given pyruvate/malate as substrates, but the effect is not significant 
(Figure 3.6B).  
The disadvantage of using isolated mitochondria from heart tissues is the potential for 
selecting a specific pool of mitochondria. Thus, we isolated adult cardiomyocytes from late 
pregnant mouse hearts, and treated the cells with saponin, a membrane permeabilizer. Consistent 
with the above findings, no alterations in respiration is observed (Figure 3.6E). We conclude that 
the mitochondrial biology of late pregnant mouse hearts is not distinctively different in number, 
function, and form from non-pregnant mouse hearts. 
  
Figure 3.5: PINK1 is decreased in late pregnant mouse hearts. 
Quantitative, real-time PCR was performed from mRNA isolated from late 
pregnant mouse hearts, compared to non-pregnant controls (Ctrl: blue bars 
n=7; LP: red bars n=7, *p-value < 0.05).  
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Figure 3.6: Mitochondrial respiration capacity is not significantly altered in late 
pregnant hearts. (A and C). Isolated mitochondria from late pregnant and control rat hearts 
were assayed for respiration by the Seahorse XF Flux Analyzer after inducing states 3 and 4 
respiration. Complex I (A) and complex II respiration (C) were evaluated with 
pyruvate/malate as substrate (B and D). Isolated mitochondria from late pregnant and control 
mouse hearts were assayed for respiration. Complex I respiration was evaluated with 
pyruvate/malate (B) and palmitoylcarnitine/malate (D) as substrates. Adult cardiomyocytes 
were isolated from wild-type and late pregnant mice, and then treated with saponin to 
permeabilize the membrane before assessing respiration (E).  
95 
 
 
Substrate transporter localization and expression are unchanged in late pregnancy 
Substrate switch often occurs concurrent with alterations in the expression of metabolic 
proteins. Quantitative, real-time PCR (qRT-PCR) demonstrated no change in the expression of 
genes involved in glucose uptake, GLUT1 or GLUT4, or lactate uptake, MCT1 and MCT4, in 
late pregnant mouse hearts (Figure 3.7A). However, CD36, the transporter that imports fatty 
acids, is moderately but significantly induced.  
  
Figure 3.7: Moderate effects of pregnancy on fatty acid uptake and oxidation genes. 
Quantitative, real-time PCR was performed on mRNA isolated from late pregnant mouse 
hearts and then compared to non-pregnant controls. Genes for the following pathways were 
assayed: (A) substrate transporter expression; (B) fatty acid uptake and oxidation; (C) 
triacylglycerol breakdown and synthesis; (D) transcription factors. (Ctrl: blue bars n=7; LP: 
red bars n=7, *p-value < 0.05).  
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Figure 3.8: Antibody verification in GLUT4 and CD36 
knockout animals. Total cell lysates were collected from 
GLUT4 and CD36 knock out mice hearts and antibodies 
were tested for GLUT4 (A) protein expression by Western, 
CD36 protein expression by Western (B), and CD36 
immunofluorescence (C).   
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Western blot analysis of GLUT4 and CD36 demonstrated no difference in protein expression 
(Figure 3.9 and 3.10). Confirmation of these antibodies for western blot and histology were made 
in the hearts of GLUT4 and CD36-null mice (Figure 3.8), kindly provided by Dr. Barbara Kahn 
(GLUT4) and Dr. Jack Lawler (CD36). Other fatty acid uptake and oxidation genes, such as 
CPT1, MCAD, FABP4 and FABP5, are also mildly upregulated, while no change is observed for 
others, including ACSL and FATPs (Figure 3.7B). These results suggest that while no striking 
differences in gene expression are observed, there is a moderate signal for fatty acid oxidation. 
A key regulatory point for substrate switch is the uptake of substrates. GLUT4 and CD36 
allow entry of glucose and fatty acid through the plasma membrane. At basal states, these 
transporters reside predominantly in intracellular vesicles. Though there is no change in total 
protein expression of GLUT4 or CD36, their presence on the plasma membrane could be 
affected in late pregnancy. There is no evidence of transporter movement by histological analysis  
 
Figure 3.9: CD36 expression in mouse and rat pregnancies. (A) Total cell lysate was 
collected from day 19 of pregnancy and control rat hearts and then assayed by Western blot 
for CD36 expression. (B) Total cell lysate was collected from mouse hearts at day 12, day 
18, and postpartum day 2 of pregnancy and then assayed by Western blot for CD36 
expression. No significant changes were observed.  
98 
 
 
 
(Figure 3.11A). Furthermore, subcellular fractionation studies on late pregnant mouse hearts 
showed no difference in GLUT4 localization (Figure 3.11B). We conclude that transporter 
localization is not a factor affecting the switch in energy source in late gestation. 
 
Triglyceride synthesis and breakdown in late pregnancy 
The increase in serum triglycerides suggests that triglyceride synthesis or storage 
pathways in the late pregnant heart could be activated. No change is observed in expression of 
AGPATs, DGATs, or lipin-1 (Figure 3.7C). Microsomal triglyceride transfer protein (mttp), 
which is involved in the export of triglycerides from the heart and known to be protective against 
lipotoxicity, is significantly induced by approximately 1.2-fold (Figure 3.7C). Furthermore, 
transcriptions factors responsible for the upregulation of fatty acid oxidation, such as PPARα, 
PPARδ, and PGC-1α also are not altered in late pregnancy (Figure 3.7D).   
Figure 3.10: GLUT4 expression in mouse and rat pregnancies. (A) Total cell lysate was 
extracted from rat hearts at day 12, day 19, and postpartum day 1 of pregnancy and then 
assayed by Western blot for GLUT4 expression. (B) Total cell lysate was collected from 
mouse hearts at day 12, day 18, and postpartum day 2 of pregnancy and then assayed by 
Western blot for GLUT4 expression. No significance was observed.  
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Figure 3.11: No change in localization of GLUT4 and CD36 in late pregnancy. (A) 
Mouse hearts were harvested from day 18 pregnant mice, compared to their non-pregnant 
controls. Histological analyses were conducted on OCT frozen mouse heart sections. 
GLUT4 and CD36 antibodies were used for staining. (B) Subcellular fractionation of late 
pregnant mouse hearts and their non-pregnant controls was conducted with different rounds 
of ultracentrifugation. The plasma membrane (PM, P1 and P2) was separated from 
intracellular vesicle fractions (IV, 1-14). Na/K ATPase was used as a plasma membrane 
marker. All fractions were blotted with GLUT4 to examine localization. Quantification of 
the abundance of GLUT4 on the PM versus IV (PM/IV) is shown (B). Ctrl (n=2), LP (n=3).  
100 
 
Late pregnancy promotes expression of PDK4  
Approximately 50% decrease in flux from glycolysis was observed in the 13C-tracer studies 
(Chapter 1). PDH controls the glycolytic contribution to the TCA cycle by converting pyruvate 
into acetyl CoA. As previously described, PDK4 can phosphorylate PDH to inhibit entry of 
carbons from glycolysis. We used qRT-PCR to assess the expression genes from the PDK 
family, the PDP family, and the FOXO family. There is a muscle-specific induction of PDK4 in 
late pregnancy (Figure 3.12). Consistent with this, a significant decrease in PDP1 and PDP2 is  
  
Figure 3.12: Muscle-specific induction of PDK4 in late pregnancy. Quantitative, real-time 
PCR was conducted on mRNA isolated from day 18 pregnant mouse tissues, including the 
heart, gastrocnemius, liver, and lung compared to their corresponding non-pregnant controls. 
(Ctrl n=7, LP n=7, *p-value < 0.05) 
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Figure 3.13: Induction of PDK4 expression is specific to late pregnancy. Hearts were 
harvested from different timed pregnancy samples from mice (A, days 8, 12, 18 of pregnancy 
and postpartum days 2 and 8) and rats (B, day 20 of pregnancy and postpartum day 1), mRNA 
was isolated and qRT-PCR was conducted to study gene expression. Verification of the PDK4 
antibody was completed with PDK2 KO, PDK4 KO, and DKO (double knock out) mice (C) in 
starved (S) or fed (F) conditions. Western blot of PDK4 protein expression was conducted (D) 
with total cell lysates of timed pregnant mouse hearts. Quantification of PDK4 expression in 
late pregnancy is shown (E). (*p-value < 0.05). 
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observed in the heart, although only PDP2 is decreased in the skeletal muscle. FOXO3 is also 
significantly increased in gastrocnemius, but not in the heart. 
A pregnancy time course evaluation of PDK4 expression shows that the response is 
targeted to late pregnancy, while downregulation is observed at postpartum day 8 (Figure 
3.13A). Interestingly, this trend does not occur in rat pregnancies, as PDK4 is induced 
specifically at postpartum day 1 (Figure 3.13B). Protein expression of PDK4 shows an 
approximately 6-fold increase (Figure 3.13D and E). Verification of the antibody was completed 
on samples from PDK4-null mouse hearts, PDK2-null mouse hearts, and double knock out 
(DKO) hearts in the starved (S) and fed (F) conditions, kindly provided by Dr. Adam Wende 
(Figure 3.13C). Furthermore, downstream phosphorylation of PDH at serine 293 is shown in 
Figure 3.14, indicating that PDK4 activity is also upregulated. After observing PDK4 induction 
in late pregnancy, we re-analyzed the 13C metabolic flux analysis of Langendorff perfused hearts 
Figure 3.14: PDH is phosphorylated in late pregnancy. Western blot of late pregnant mouse 
hearts for phosphorylated (Serine 293) and total pyruvate dehydrogenase (PDH) in two sets of 
late pregnant mouse hearts. (*p-value < 0.05) 
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from Chapter 1 to specifically determine the input of labeled carbons from pyruvate into the 
TCA. There is a significant decrease in pyruvate entry into the TCA cycle (Figure 3.15).  
 
Progesterone induces PDK4 in NRVMs 
Induction of PDK4 specifically in late pregnancy suggests that the hormonal milieu could 
potentiate the response. Isolated neonatal ventricular myocytes (NRVMs) were used to determine 
the effects of hormones on PDK4 gene expression. Progesterone and estrogen have been well 
characterized to be elevated during late pregnancy. NRVMs were treated with physiological 
levels of progesterone and estrogen for 1-48 hours (Figure 3.16). Striking upregulation of PDK4 
is observed after 4-8 hours of progesterone treatment. Furthermore, estrogen induces PDK4 but 
not as strongly as progesterone. Prolactin incubated on NRVMs did not induce PDK4 (data not  
Figure 3.15: Pyruvate flux into the TCA cycle is 
inhibited during late pregnancy. From 
Langendorff perfused hearts data in Chapter 1, we 
determined the pyruvate flux into the TCA cycle. 
The presence of the m2 isotopomer of citrate (as a 
surrogate for acetyl CoA) was compared to the m3 
isotopomer of pyruvate in non-pregnant and late 
pregnant mouse hearts to determine entry of 
pyruvate into the TCA cycle.  
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Figure 3.16: PDK4 is induced by progesterone at different time points in NRVMs. 
NRVMs were treated with 100 ng/mL of progesterone (PG) or 100 pg/mL β-estradiol (βE) 
for 1 hour, 4 hour, 8 hour, and 48 hours, and then assessed for gene expression with qRT-
PCR.  
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shown). Treatment of isolated mouse adult cardiomyocytes, however, did not induce PDK4 
(Figure 3.17), but the challenges of long-term culture of adult cardiomyocytes may contribute to 
the results presented here. MCF7s, a breast cancer cell line, also do not respond to progesterone 
treatment (Figure 3.18). C2C12s, a myoblast cell line that can be differentiated to myotubes, 
were also incubated with progesterone and estrogen. Mild induction of PDK4 is observed at 24 
hours (Figure 3.19). This indicates that the striking PDK4 response to progesterone is cardiac 
specific.   
The downstream effects of progesterone can be mediated through both progesterone 
receptor and non-receptor pathways. To determine if the progesterone receptor plays a role in 
PDK4 induction, we used a receptor antagonist, mifepristone (RU486) to pre-treat NRVMs for 1  
Figure 3.17: PDK4 is not induced in adult cardiomyocytes. Cardiomyocytes were isolated 
from C57/bl6 mice, and then treated with progesterone (PG) or β-estradiol (βE) for 8 or 24 
hours in media containing MEM, insulin transferrin selenium (ITS), glutamine, NaHCO3, 
HEPES, 0.2% BSA, and blebbistatin. Then quantitative, real-time PCR was performed to 
assess gene expression.  
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Figure 3.18: No change in PDK4 expression in MCF7 cells with progesterone. MCF7 
cells were treated with 100 ng/mL progesterone (PG) or 100 pg/mL β-estradiol (βE) for 4 
hours and 8 hours and then analyzed with qRT-PCR. 
Figure 3.19: Mild effects of progesterone on PDK4 expression in C2C12s. C2C12 cells 
were treated with 100 ng/mL progesterone (PG) or 100 pg/mL β-estradiol (βE) for 12 hours 
and 24 hours and then analyzed with qRT-PCR. 
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hour, followed by progesterone incubation for 8 hours. Mifepristone attenuated the induction of 
PDK4 by approximately 50%, suggesting that progesterone-mediated effects is through the 
receptor (Figure 3.20). Antagonist alone also lead to an increase in PDK4 expression, not 
surprisingly because mifepristone in the absence of progesterone is known to behave as an 
agonist.  
 
Discussion 
Our study shows that in late pregnancy, PDK4, a crucial enzyme that governs the entry of 
glycolytic products into the TCA cycle, is upregulated in a muscle-specific manner. This is 
possibly in response to high serum progesterone levels. In addition, it occurs in the absence of 
changes in mitochondrial content and respiration capacity, GLUT4 and CD36 transporter 
expression and translocation, and factors involved in triglyceride synthesis and turnover.  
We had hypothesized that due to the increased cardiac output in late pregnancy, the 
increased ATP demand would result in mitochondrial adaptations and enhanced respiration. The 
comparable respiration we observed in late pregnancy is also accompanied by lack of induction 
in genes involved in mitochondrial biogenesis, such as PGC-1α. This was surprising because in 
exercise, for example, increased work load results in mitochondrial biogenesis and greater 
respiratory capacity (Han and Kim, 2013; Tonkonogi et al., 2000). The only study on cardiac 
mitochondria of pregnancy stained late pregnant rat hearts with tetramethylrhodamine (TMRM), 
and then used confocal microscopy to quantify the length and width of mitochondria (Bassien-
Capsa et al., 2006). They did not observe any differences. However, no group has assayed for 
respiration or proteins of the ETC complex. A previous study of cardiac-specific Ndufs4-null 
mice, which lack the ability to assemble complex I of the ETC, reported a heart failure 
phenotype in female mice with multiple pregnancies (Karamanlidis et al., 2013). This suggests  
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Figure 3.20: PDK4 induction by progesterone is mediated through the progesterone 
receptor. (A) Mifepristone, a known progesterone receptor antagonist, was pre-treated 
on NRVMs for 1 hour before addition of 100 ng/mL progesterone (PG) or 100 pg/mL β-
estradiol (βE) for 8 hours. (B) After 9 hours of treatment, mRNA was isolated from 
NRVMs and assessed for gene expression by qRT-PCR.  
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that oxidative phosphorylation is vital for the increased demands of pregnancy. Overall, our 
results indicate that the increased work load of late pregnancy do not exceed the capabilities of 
the mitochondria and thus biogenesis is not necessary to satisfy demands.  
There is a discrepancy between these results and subsequent data on PDK4 induction in 
late pregnant mouse hearts. An induction of PDK4 would prevent pyruvate input into the TCA 
cycle, and thus should lead to a decrease in respiration with pyruvate/malate as the substrate for 
isolated mitochondria. A trend towards decreased maximal and basal respiration can be seen in 
these isolated mitochondria that is consistent with PDH inhibition, but it is not significant. Thus, 
increasing sample size for each group may be necessary to observe a change. It is also possible 
that the technical process of mitochondrial isolation and centrifugation affected the 
phosphorylation state of PDH and resulted in loss of inhibition by PDK4. This ambiguity can be 
resolved by assessing the phospho-PDH state in isolated mitochondria. It is also worth noting 
that in our studies, maximal respiration with FCCP treatment is not greater than basal respiration 
(state 3), as would be expected. This commonly occurs in isolated mitochondria from the heart 
and could be due to limiting substrate concentrations in the assay solution.  
Transporter translocation in response to insulin or contraction is well established to 
regulate substrate intake. Thus, we determined if differences in localization could contribute to 
the shift in usage. A modest, but significant induction in CD36 gene expression is observed, but 
GLUT4 is unchanged. However, protein expression did not detect differences in either 
transporter in late pregnancy. Previous studies found that increased CD36 expression in C2C12 
cells induced PDK4 and FOXO1 expression, but this does not occur in late pregnancy (Nahle et 
al., 2008). There is also no change in localization of transporters. This suggests that transporter 
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localization does not regulate substrate switch in late pregnancy. It is worth noting that both 
mouse and rat hearts display parallel phenotypes.  
Fatty acids that enter the cardiomyocyte have two fates: to continue on to β-oxidation in 
the mitochondria or be stored as a triglyceride. We did not detect any alterations in gene 
expression of factors in triglyceride storage or turnover in late pregnant mouse hearts. One 
modest increase was in the gene mttp. Interestingly, this protein is involved in the export of 
triglycerides and can be protective against lipotoxocity. It thus plays a role in preventing build-
up of deleterious lipids that enter the heart during late pregnancy. There have been no reports of 
the effect of pregnancy on genetically manipulated mice with deletions in genes involved in 
triglyceride synthesis or break down, but it would be interesting to determine how metabolic flux 
is altered in these mice, and could elucidate the importance of the triglyceride pool as an energy 
resource in late pregnancy. Total triglyceride content and the presence of different lipid species 
in late pregnant mouse hearts have also not been characterized. Overall, we surmise that modest 
gene expression changes define the late pregnant heart. This is consistent with a previous study 
that studied the entire profile of late pregnant mouse hearts with microarray analysis (Chung et 
al., 2012a). If regulations in these pathways do occur, perhaps protein expression or 
posttranslational modifications should be examined.  
A vital enzyme that connects glycolysis to the TCA cycle is PDH (Zhang et al., 2014). It 
is highly regulated by families of kinases (PDKs) and phosphatases (PDPs). Interestingly, we 
observe an increase in PDK4 in late pregnancy, the prominent isoform in the heart. This 
induction is strongest in the heart, compared to the gastrocnemius muscle, but is lacking in other 
tissues, like liver and lung. The phosphatase that reverses the inhibition, the PDP family, is 
oppositely regulated and is decreased in late pregnant mouse hearts. Consistent with this, 
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phospho-PDH at serine 293 to total PDH ratios were also increased in late pregnancy, indicative 
of increased PDK4 activity. Importantly, this induction is specific to the late pregnancy state in 
mice, as with PDK4 induction. PDH is also phosphorylated at two other serine sites (ser232 and 
ser300), though we have not explored the degree of phosphorylation in late pregnant mouse 
hearts. Furthermore, other post-translational modifications of PDH, such as acetylation, has been 
shown (Jing et al., 2013). Acetylation can affect the phosphorylation status and thus activity of 
PDH. We have not directly determined activity of PDH – the degree of phosphorylation can 
affect the activity and stringency of inhibition.  
Interestingly, FOXO3 is upregulated in gastrocnemius muscle but not in cardiac muscle. 
FOXO1 has been shown to induce PDK4, so perhaps this indicates that PDK4 induction in 
skeletal muscle and cardiac muscle are via two different pathways. FOXO3 has not been greatly 
characterized in its role in PDK4 induction, although one study in colon cells found that 
overexpression of FOXO3 resulted in increased PDK4, but if the same is true in skeletal muscle 
is unknown (Ferber et al., 2012). Though we do not observe PDK4 differences in the liver and 
lung, PDP2 is significantly but oppositely changed in both tissues. Looking at downstream PDH 
phosphorylation states may shed light on the significance of these changes.  
It is worth noting that mouse and rat physiology in pregnancy could be different. Two 
groups that examined late pregnant rat hearts found no change in PDH activity or PDK4 gene 
expression (Nieuwenhuizen et al., 1998; Rimbaud et al., 2009; Sugden and Holness, 1993a). In 
addition, they observed no GLUT4 or PGC-1α upregulation, but did see decreases in CPT-1 and 
mcad. In our rat heart samples, there was no induction in PDK4 at late pregnancy (D18), 
consistent with previous studies, but we did detect induction at postpartum day 1. Because a 
similar substrate switch was determined in late pregnant rat hearts by others, a PDK4-
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independent mechanism must be present. It is possible that the “Randle cycle” is responsible, 
where increased concentrations of fatty acids can rapidly affect glucose utilization. Other 
potential mechanisms are further postulated in Chapter 4. Hence, it is important to be aware of 
differences in between rat and mouse hearts during pregnancy.  
PDK4 upregulation is consistent with our 13C-tracer analysis from Chapter 1, in which we 
observed decreased glucose and increased fatty acid utilization. To further extrapolate this from 
the data, we determined the amount of labeled citrate that forms from 13C-glucose perfusion in 
late pregnant and control hearts, and found that there is a decrease in pyruvate entry into the 
TCA cycle. This is accomplished by substituting the m2 isotopomer species of citrate for acetyl 
CoA and comparing it to the m3 isotopomer of pyruvate. Ideally, the TCA contributed m2 
isotopomer of citrate (which is the m2 isotopomer of oxaloacetate that combines with an 
unlabeled acetyl CoA) should be subtracted and account for, but we determined that these 
contributions were negligible. Thus, in order to establish if PDK4 is responsible for the substrate 
switch state observed at late gestation, it is necessary to determine metabolic flux in pregnant 
PDK4-null mice. We would expect mice without PDK4 to be unable to decrease glucose 
utilization. However, PDK2 is also highly expressed in hearts, as observed from the western blot 
with PDK antibody, and potential compensation could be made. Perhaps determining PDH 
activity in PDK2 and PDK4 KO mouse hearts will shed light on importance of the two in the 
heart. However, starved PDK4-deleted mice do not increase PDK2 expression, so compensation 
may not occur.   
To further explore mechanistic details of PDK4 induction, we used the NRVMs model. 
The hormonal milieu is responsible for reprogramming maternal physiology during pregnancy. 
Thus, we sought to see if this is also true for PDK4 induction. Progesterone and estrogen are 
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both known to be elevated at late pregnancy (Chung and Leinwand, 2014; Chung et al., 2012b). 
Treatment of NRVMs with progesterone and estrogen showed that while both can upregulate 
PDK4, progesterone is a stronger and more consistent inducer. It is interesting to note that 
prolactin does not increase PDK4. One group found that in adipose cells, treatment with 
prolactin induced PDK4 expression via STAT5 (White et al., 2007). Progesterone receptor 
antagonist (mifepristone) treatment diminished the PDK4 effects. This induction is not observed 
in adult cardiomyocytes treated with progesterone. However, these cells in culture were treated 
with blebbistatin, an inhibitor of contractility (Kabaeva et al., 2008). This compromises the 
metabolic phenotype in isolated cells, and thus conclusions in adult cardiomyocytes are not 
reliable.  
From these studies, we conclude that PDK4 is induced in late pregnant mouse hearts, and 
glucose utilization is decreased. Whether or not these two conclusions are causally linked is not 
clear. Future experiments to elucidate this will include using genetically manipulated mouse 
models with PDK4 deleted or inhibitors of PDK4, a commonly used one is dichloroacetate 
(DCA). Pregnancy in these mice followed by 13C tracer analysis will allow us to conclude how 
important PDK4 induction is in late pregnancy. Furthermore, to explore if the in vitro data of 
progesterone induction of PDK4 in NRVMs is representative of in vivo phenotypes, we propose 
injecting progesterone or estrogen into ovariectomized mice to determine gene expression 
profiles of the heart.  
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Materials & Methods 
Animal studies. All animal studies were performed according to procedures approved by the 
Institutional Animal Care and Use Committee (IACUC) at Beth Israel Deaconess Medical Center 
(BIDMC). Mice were maintained on a standard rodent chow diet with 12 hours light and dark 
cycles with water and food ad libitum. C57/bl6 mice were purchased from Jackson Laboratories 
(Bar Harbor, Maine). Wild-type, three-month-old female C57/bl6 undergoing estrus were mated 
with wild-type, C57/bl6 breeder males. The presence of a copulatory plug is denoted as day 0 of 
pregnancy. Pregnant females were singly placed in a new cage, and breeder diet (Formulab 
5058) replaced the standard chow (Formulab 5008) they were previously on, unless delineated 
differently elsewhere. Breeder diet contains more fat and calories compared to standard chow. 
Timed pregnancies were carried out to day 11-12 (mid-pregnancy) and day 17-18 (late 
pregnancy) of gestation. Timed pregnant rats (Sprague Dawley) were obtained directly from 
Charles River.  
Reagents and Materials. Unless otherwise stated, all reagents are from Sigma. GLUT4 and 
CD36 deleted mouse tissues were kindly provided by Dr. Barbara Kahn and Dr. Jack Lawler. 
PDK4 KO, PDK2 KO, and DKO mouse tissues were generously provided by Dr. Adam Wende. 
Dr. Robert Harris kindly gave us the PDK4 antibody.  
Isolated mitochondria. Mitochondria were isolated from mouse and rat hearts as previously 
described. Hearts were rinsed in 2 mL of the mitochondrial isolation buffer (MIB) (70 mM 
sucrose, 210 mM mannitol, 5 mM HEPES, 1 mM EGTA, 0.5% (w/v) fatty acid free BSA, pH 
7.2), and then transferred to 2 mL of fresh MIB. Tissue was homogenized with Teflon pedestal, 
programmed to drill at high speed with 3-4 dounces. Homogenate was spun at 1000 rpm for 10 
minutes at 4oC. Supernatant was transferred to a new tube and spun at 8000 rpm for 10 minutes 
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at 4oC. The pellet was resuspended in approximately 100µL of MIB. Samples were spun again as 
before. Pellet was then resuspended into 50µL of MIB and then brought up to 550 µL of 
mitochondrial assay solution (MAS) (70 mM sucrose, 220 mM mannitol, 10mM KH2PO4, 5 mM 
MgCl2, 2 mM HEPES, 1 mM EGTA, and 0.2% (w/v) fatty acid free BSA, pH 7.2). Mitochondria 
was quantified using Bradford and approximately 2 µg of protein was loaded onto the Seahorse 
plate and spun at 2000 rpm for 10 minutes at room temperature.  
Seahorse experiments. Mitochondrial respiratory function experiments were performed on a XF 
Flux Analyzer (Seahorse Biosciences). Isolated mitochondria was plated at 2µg per well and 
isolated cardiomyocytes were plated at 20,000 cells per well (Readnower et al., 2012). To assay 
complex I respiration, 10mM pyruvate and 2mM malate was used. State 3 respiration was 
induced with 4mM ADP, followed by state 4o respiration with 3µM oligomycin. Then, 4µM of 
the uncoupler FCCP produced maximal respiration and lastly 2µM of rotenone and antimycin A 
was utilized to inhibit respiration. Fatty acid oxidation respiration rates were determined with 
50µM palmitoylcarnitine and 0.5mM malate, which preceded the addition of the complex I 
respiration substrates. For isolated cardiomyocytes, 10µg/mL saponin was used to permeabilize 
the membrane, and then the inhibitors described were treated on cells.  
Gene expression studies. Upon harvesting, mouse tissues were immediately frozen in liquid 
nitrogen. Total RNA was isolated from with the TRIzol (Invitrogen) and chloroform method. 
RNA concentrations were measured with the ThermoScientific NanoDrop spectrophotometer, 1 
µg of RNA was used to synthesize cDNA with the High-Capacity cDNA Reverse Transcription 
kit (Applied Biosystems, CA). Gene expression was assayed with quantitative, real-time PCR 
using SYBR Green dye with specific primer set specially designed and the Bio-rad CFX 384 
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Touch Real-Time PCR Detection System. The primers used for mice and rats are listed in Tables 
3.1 and 3.2.  
Western blots. To determine protein expression, frozen mouse tissues were homogenized in the 
Qiagen TissueLyser for 10-15 minutes in RIPA lysis buffer, in the presence of phosphatase and 
protease inhibitors. Protein concentration was determined by the Bradford assay. Approximately 
10 µg of protein were separated by SDS-PAGE, before transferred onto PVDF membrane. The 
primary antibodies were for immunoblot were: GLUT4 (Millipore), CD36 (Novus), PDK4 (a 
kind gift from Dr. Robert Harris), phospho-PDH at serine 293 (Novus), PDH (Cell signaling), 
Na+/K+ ATPase (Novus).  Primary antibodies were incubated overnight at 1:1000. Three TBS-T 
washes were conducted before incubating with secondary antibody at 1:10,000 for 1 hour. 
Vinculin (Cell signaling) and GAPDH (Santa Cruz) were used as loading controls.  
Histological studies. Hearts were excised from mice and rinsed in cold phosphate-buffer saline 
(PBS). Tissue was embedded in optimal cutting temperature (OCT) and then 10 µm sections 
were cut. Fixation with 4% PFA was carried out for 15-30 minutes. Blocking was with 3% 
BSA/PBS + 0.1% Triton-X for 1 hour at room temperature. Primary antibodies used were 
GLUT4 (Santa Cruz, 1:100 and 1:500) and CD36 (Cayman, 1:100 and 1:500).  
Subcellular fractionation. Subcellular fractionation was carried out as previously described 
(Matsui et al., 2006; Zhou et al., 1998). Briefly, heart tissue was removed from mice and then 
immediately placed chilled HES buffer (20 mM HEPES, 250 mM sucrose, 1 mM EDTA) with 
protease inhibitors and then homogenized. Samples were then centrifuged at 2000g for 10 
minutes at 4oC. The supernatant is transferred to a new tube, where it is then centrifuged at 
9000g for 20 minutes at 4oC. The pellet (P1) is the plasma membrane fraction. The supernatant is 
ultracentrifuged at 180,000g for 90 minutes. The supernatant is the cytosol component and the 
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pellet is then resuspended in PBS and protease inhibitors and then loaded onto a 10-30% 
continuous sucrose gradient. It is then centrifuged further at 48,000 rpm for 55 minutes. The 
pellet (P2) is the plasma membrane, whereas the supernatant was separated in to 10-15 fractions 
and make up the intracellular vesicles.  
Cells culture. C2C12 cells were purchased from ATCC and grown in DMEM, 10% fetal bovine 
serum (FBS) before differentiation for 2 days with insulin and transferrin and 2 days with 2% 
horse serum (HS). MCF-7 cells were grown in DMEM, 10% FBS before and during treatment.  
Neonatal cardiomyocyte isolations. Neonatal cardiomyocyte isolations were carried out as 
previously described (Hajjar et al., 1997). Briefly, hearts of 1-2 day old Sprague Dawley 
neonates were excised and ventricles were isolated. Sequential incubations with collagenase type 
II (Worthington) were carried out in a 37oC shaker. Cells were purified from non-
cardiomyocytes via a crude, 1 hour pre-plating step. Cells were then incubated in DMEM, 10% 
HS, 5% FBS, and 1% penicillin-streptomycin (PS).  
Adult cardiomyocyte isolations. Adult mouse hearts were excised and perfused via 
Langendorff perfusion, first with perfusion buffer (137 mM NaCl, 4 mM KCl, 1 mM MgCl2, 10 
mM HEPES, 0.33 mM NaH2PO4, 10mM glucose, 5 mM taurine, and 10 mM BDM), before 
switching to an enzyme buffer with collagenase D (Roche), collagenase B (Roche), and protease 
XIV for 10-15 minutes. Calcium was reloaded with concentrations of 0.06 mM, 0.25 mM, 0.60 
mM, and 1.2 mM. Adult cardiomyocytes were plated on laminin-coated tissue culture plates for 
2 hours in MEM (Invitrogen), 10% calf serum, BDM, 2 mM glutamine, and 2mM ATP before 
switching to labeled media.  
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Table 3.1 Mouse qRT-PCR primers 
PRC GGAAGACTTTGATCCTGCTCCTG 
GGTTGGAAGAGGCTGGACACCTCC 
TBP CCCTATCACTCCTGCCACACCAGC 
GTGCAATGGTCTTTAGGTCAAGTTTACAGCC 
β-actin CCCTGTATGCCTCTGGTCGTACCAC 
GCCAGCCAGGTCCAGACGCAGGATG 
36B4 GGAGCCAGCGAGGCCACACTGCTG 
CTGGCCACGTTGCGGACACCCTCC 
ND1 GTGGCTCATCTACTCCACTGA 
TCGAGCGATCCATAACAATAA 
ND2 ACCCACGATCAACTGAAGC 
TGTTTATAGTTGAGTACGATGGCC 
cyt b CATTTATTATCGCGGCCCTA 
TGTTGGGTTGTTTGATCCTG 
COX1 CTAGCCGCAGGCATTACTAT 
TGCCCAAAGAATCAGAACAG 
COX2 GCCGACTAAATCAAGCAACA 
CAATGGGCATAAAGCTATGG 
ATP6 GACGAACATGAACCCTAAT 
TACGGCTCCAGCTCATAGT 
GLUT1 GCCCCCGACAGAGAAGATG 
CAGTTCGGCTATAACACTGGTG 
GLUT4 GTGACTGGAACACTGGTCCTA 
CCAGCCACGTTGCATTGTAG 
CD36 GGCACAGACGCAGCCTCCTTTCCACC 
GGTGATGCAAAGGCATTGGCTGG 
FATP1 TCAATGTACCAGGAATTACAGAAGG 
GAGTGAGAAGTCGCCTGCAC 
FATP4 GCAAGTCCCATCAGCAACTG 
GGGGGAAATCACAGCTTCTC 
CPT1 GGCACTGGCCGATGACGTGGAGCTC 
CAGGCAGAACTTGCCTTTGTCCCGG 
mcad CAGCTAGCACTGACGCCGTGCAG 
GCTCACGAGCTATGATCAGCCTCTG 
Fabp4 GGGGCCAGGCTTCTATTCC 
GGAGCTGGGTTAGGTATGGG 
Fabp5 TGAAAGAGCTAGGAGTAGGACTG 
CTCTCGGTTTTGACCGTGATG 
acsl1 TGCCAGAGCTGATTGACATTC 
GGCATACCAGAAGGTGGTGAG 
acsl3 CCAGCCATTGTTCATGGACTG 
TGGGACCAAAGAGACTATTTCCT 
acsl4 CTCACCATTATATTGCTGCCTGT 
TCTCTTTGCCATAGCGTTTTTCT 
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acsl5 TCCTGACGTTTGGAACGGC 
CTCCCTCAATCCCCACAGAC 
mttp CTC TTG GCA GTG CTT TTT CTC T 
GAG CTT GTA TAG CCG CTC ATT 
agpat1 TAA GAT GGC CTT CTA CAA CGG C 
CCA TAC AGG TAT TTG ACG TGG AG 
Agpat2 CAG CCA GGT TCT ACG CCA AG 
TGA TGC TCA TGT TAT CCA CGG T 
Agpat3 CTG CTT GCC TAC CTG AAG ACC 
GAT ACG GCG GTA TAG GTG CTT 
Agpat4 CCA GTT TCT ATG TCA CCT GGT C 
GCA GAG TCT GGC ATT GAT CTT G 
Lpin1 CAT GCT TCG GAA AGT CCT TCA 
GGT TAT TCT TTG GCG TCA ACC T 
Dgat1 GCC TTA CTG GTT GAG TCT ATC AC 
GCA CCA CAG GTT GAC ATC C 
Dgat2 GCG CTA CTT CCG AGA CTA CTT 
GGG CCT TAT GCC AGG AAA CT 
Atgl CAA CGC CAC TCA CAT CTA CGG 
GGA CAC CTC AAT AAT GTT GGC AC 
PDK1 GGA CTT CGG GTC AGT GAA TGC 
TCC TGA GAA GAT TGT CGG GGA 
PDK2 AGGGGCACCCAAGTACATC 
TGCCGGAGGAAAGTGAATGAC 
PDK3 TCCTGGACTTCGGAAGGGATA 
ACCTCTCTCATGGTGTTAGCC 
PDK4 
(same for rats) 
CCGCATTTCTACTCGGATGC 
CGATACTTCCAATGTGGCTTGG 
PDP1 GCA CCC ATA GAG GAC CGG A 
CCT GCA TGA CCA TCA AAA ACC C 
PDP2 ACT GTG TCC TAC TGG ATC TTC AA 
CAG GTT CCT ACT CGT GGC A 
FOXO1 CCC AGG CCG GAG TTT AAC C 
GTT GCT CAT AAA GTC GGT GCT 
FOXO3 GCA AGC CGT GTA CTG TGG A 
CGG GAG CGC GAT GTT ATC C 
 
 
Table 3.2 Rat qRT-PCR primers 
HPRT GGTGAAAAGGACCTCTCGAAG 
GCTTTTCCACTTTCGCTGATG 
GAPDH AACGACCCCTTCATTGACCTC 
CCTTGACTGTGCCGTTGAACT 
PDK1 CGAGACGGCTTTGTGATTTG 
GTGATAGAGATGGGACGGAAC 
Table 3.1 (continued) 
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In this thesis, we determined the metabolic state and regulations of late pregnancy in 
mice. We observed higher serum triglyceride levels, concurrent with increased uptake of fatty 
acids in late pregnancy. In the heart, this coincides with intrinsic cardiac alterations that results in 
decreased glucose utilization and moderate increase in fatty acid utilization. How this substrate 
switch occurs was then explored. We found that the mitochondrial biology of late gestation is not 
significantly different from the non-pregnant state. Furthermore, there is no alteration in GLUT4 
and CD36 transporter status or gene expression of factors involved in the triglyceride synthesis 
or turnover pathway. Interestingly, we found that pyruvate dehydrogenase kinase 4 (PDK4) is 
induced by ~4-fold in late pregnant mouse hearts. PDK4 is a crucial regulatory enzyme that can 
affect glycolytic product input into the TCA cycle by phosphorylation of pyruvate 
dehydrogenase (PDH). Pyruvate dehydrogenase phosphatases, activators of PDH through 
dephosphorylation, was oppositely regulated and significantly decreased. This effect is specific 
to heart and skeletal muscle in late gestation. Lastly, we determined that the pregnancy hormone 
progesterone can promote PDK4 upregulation by the progesterone receptor in isolated 
cardiomyocytes. These studies demonstrate that the substrate switch of late pregnancy could be 
promoted by PDH inhibition via PDK4.  
 
Increased uptake and β-oxidation of fats in late pregnant mouse hearts 
The continuous contraction of the heart muscle results in high metabolic demands. With 
low energy reserves available, it is especially important that it is never lacking for substrate 
source. Fortunately, the heart is extremely flexible and can utilize many different substrates 
depending on the condition. For example, in the increased workload of exercise, the myocardium 
uses abundant lactate sources to fulfill its needs (Gertz et al., 1988; Stanley, 1991). During times 
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of metabolic inflexibility, however, as in pathological states, it has been evident that 
compromises in meeting energy needs is strongly linked to cardiac dysfunction. Thus, the 
importance of maintaining sufficient cardiac metabolism during both physiological and 
pathological states is critical to ensuring that contractile function can be preserved. 
In pregnancy, maternal physiology drastically changes. Systemic insulin resistance shifts 
maternal substrate usage to increase fat usage in order to facilitate fetal preferences for glucose 
(King, 2000). In addition, cardiac output, which peaks by early to mid-trimester, is sustained to 
the end of pregnancy (Melchiorre et al., 2012). Thus, both fetal needs and greater ATP demands 
on the maternal myocardium indicates that adaptations must occur to sustain this for the duration 
of pregnancy.  However, the metabolic phenotype of the heart during pregnancy has not been 
greatly explored.  
Previously published work demonstrated that late pregnant dog and rat hearts decrease 
glucose utilization and increase fatty acid oxidation (Sugden and Holness, 1993a; Williams et al., 
2008). We confirm these findings using two novel techniques, which have not been used before 
to study cardiac metabolism during pregnancy. With a luciferase-based in vivo, real-time 
bioluminescence imaging system, we were able to detect both faster dynamics and greater 
overall uptake in fatty acids in late pregnant mouse hearts. This, however, is not paralleled by an 
increase in CD36 transporter expression or localization. This raises an interesting point: while we 
observe an increase in the source and sink of fatty acids in late pregnancy, the means by which 
they enter the cell is not altered. This indicates that there must be an increase in the rate of 
uptake, which we do discern in the bioluminescence studies. The second technique we utilized 
was 13C-substrate tracer analysis on ex vivo perfused pregnant mouse hearts. This is the first 
study that we know of to characterize cardiac metabolism during pregnancy by directly studying 
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flux through glycolysis and the TCA cycle. With this tool, we corroborate the findings of 
previous groups. We can also conclude from perfused hearts that there are intrinsic cardiac 
adaptations that occur in late pregnancy, independent of the substrate environment of the cell.  
Both the sensitivity and speed in the simultaneous detection of many intermediates, and 
the flexibility in assaying many different conditions make 13C-tracer analysis a valuable tool to 
study cardiac metabolism. Here, we scrutinize only glucose and fatty acids as substrate sources 
for the late pregnant mouse heart. However, it is well-known that the healthy heart utilize 
pyruvate and lactate as well, and thus labeling of these substrates will elucidate if other 
carbohydrate sources is compensating for the decrease in glucose usage that we observe 
(Khairallah et al., 2004). Furthermore, our perfusion buffer contains only one type of fatty acid, 
palmitic acid. The most common fatty acid is oleate and using either labeled oleate or a cocktail 
of labeled fatty acids may be closer to physiology. 
 
Metabolic dysfunction in pregnancy-related cardiac diseases 
Peripartum cardiomyopathy (PPCM), diagnosed by the onset of heart failure in late 
gestation or immediately postpartum, is a disease with unknown etiology. Recent work by our 
lab and others have led to the hypothesis that PPCM is caused by pathological capillary 
adaptations in the heart (Halkein et al., 2013; Hilfiker-Kleiner et al., 2007; Patten et al., 2012). 
Two common models for PPCM, for example, is the cardiac PGC-1α- and the STAT3-deleted 
mice. Both models develop heart failure during late pregnancy and have pointed to vascular 
insufficiency and metabolic deficiency as a potential underlying cause of PPCM. PGC-1α is a 
transcriptional co-activator that regulates angiogenesis and mitochondrial biogenesis and 
respiration (Arany et al., 2008; Arany et al., 2005). In the skeletal muscle, PGC-1α coordinates 
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with ERRα to increase PDK4 expression during exercise or starvation (Wende et al., 2005). 
Assessment of whole-body PGC-1α knockout mice found not only significant deficiencies in 
ATP levels, but also cardiac dysfunction. STAT3 has been well-characterized to be involved in 
paracrine-mediated angiogenesis and has been found to protect against ischemia reperfusion in 
cardiomyocytes by upregulation of antioxidant enzymes. In addition, recent studies have 
determined that STAT3 is also present in the mitochondria and isolated mitochondria from mice 
with deleted STAT3 in the heart show reduced respiration (Wegrzyn et al., 2009). Thus, in both 
mouse models, significant metabolic inadequacies exist that could play a role in predisposal to 
PPCM.  
We hypothesize that ablation of PGC-1α and STAT3 in late pregnancy may compromise 
the ability of the heart to induce PDK4 and switch substrate preferences. To test this hypothesis, 
cardiac PDK4 expression levels in both PGC-1α and STAT3 deficient mice during late 
pregnancy should be established. 13C tracer studies of metabolic flux with Langendorff perfused 
hearts from each of these models can determine substrate utilization under this pathological 
setting. We expect to observe that fatty acid uptake and utilization is decreased in these mice and 
glucose utilization is increased compared to wild-type mice during late pregnancy.  
In addition, mating to cardiac-specific PDK4 overexpressing transgenic mice should 
rescue the cardiac dysfunction defects observed in late pregnancy. PDK4 overexpressing mice 
have been formerly characterized to have elevated fatty acid oxidation and diminished glucose 
utilization (Chambers et al., 2011; Zhao et al., 2008). Furthermore, they are protected against 
ischemia reperfusion and triglyceride accumulations with high fat diet. These studies would 
delineate the importance of maintaining the switch in substrate usage that occurs in late 
pregnancy and how dysregulation could lead to cardiac diseases, such as PPCM.  
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Mitochondrial function during late pregnancy 
We hypothesized the increased demand for ATP must result in adaptations in the 
machinery that generates ATP, namely the mitochondria. Furthermore, women with 
mitochondrial diseases are more prone to complications during pregnancy, such as preterm 
delivery or preeclampsia though the sample size of this study is limited (Say et al., 2011). In 
addition, female mice with deletion of a complex I protein, Ndufs4, develop heart failure after 
multiple pregnancies (Karamanlidis et al., 2013). These studies suggest that vulnerabilities in 
mitochondrial ability to adjust to energetic needs leads to pathological conditions.  
In this study, we found no significant differences in isolated mitochondrial function 
during late pregnancy compared to non-pregnant controls. Furthermore, the number per unit 
weight of the heart and mitochondrial morphology were not changed. This is consistent with a 
previous study that found no change in the size of mitochondria with confocal microscopy 
(Bassien-Capsa et al., 2006). PINK1, an enzyme that promotes mitophagy, is significantly 
decreased in late pregnant mouse hearts, but further studies are necessary to determine if 
mitophagy itself is affected as well. In addition, because we utilized a rather crude method of 
assaying mitochondria number and morphology during pregnancy, we may not be able to detect 
subtle changes in mitochondria. More stringent characterization can be made with electron 
microscopy (EM), which is the gold standard in characterizing mitochondrial dimensions, or by 
determining citrate synthase activity. Thus, we conclude that the mitochondria can withstand the 
increased demands during pregnancy. However, if preexisting defects are already present, then 
the machinery cannot sustain the added stress and demand of pregnancy, leading to cardiac 
diseases. 
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Metabolic substrate uptake during late pregnancy 
Metabolic uptake in cardiomyocytes is controlled in multiple ways, including serum 
availability, endothelial transport, and availability of metabolic transporters. We investigated and 
found no changes in the expression and localization of the glucose transporter GLUT4 and the 
fatty acid transporter CD36. Previous work showed no difference in GLUT4 expression in late 
pregnant rat hearts, but localization has not been explored (Nieuwenhuizen et al., 1998; Rimbaud 
et al., 2009). We find here no difference in transporter localization during pregnancy. This is 
surprising given the increase in fatty acid uptake.  
There are, however, modest increases in the proteins involved in fatty acid uptake, such 
as FABP4 and FABP5. These proteins are known to be expressed in the endothelium and mice 
with deletions are deficit in fatty acid uptake (Elmasri et al., 2009; Maeda et al., 2005; Masouye 
et al., 1997). Determining their expression levels in isolated cardiac endothelial cells from late 
pregnant mouse hearts would be more informative, as the induction may be diluted out by non-
endothelial cells in the heart. If an increase in endothelial expression is observed, it would 
suggest increased transport of fatty acids through the endothelium to cardiomyocytes.  
 
The role of PDK4 in cardiac metabolic switch in late pregnancy 
PDK4 has been extremely well-characterized for its role in metabolic regulation by 
phosphorylation and thus inhibition of PDH. We found a marked upregulation of PDK4 in late 
pregnant mouse hearts and a concomitant decrease in PDP2. This indicates that PDH is inhibited 
so that glycolytic product entry into the TCA is diminished. It is also consistent with our finding 
in 13C-metabolic flux analysis of late pregnant mouse hearts that intrinsic cardiac alterations 
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occur. Earlier work in pregnant rats and dogs showed divergent results. One group found no 
change in PDK4 expression in late pregnancy, while another showed decreased gene expression 
of PDH (Rimbaud et al., 2009; Sugden et al., 1992; Williams et al., 2008). However, PDH is 
regulated at post-translationally, but they did not explore the phosphorylation profile of PDH. In 
our studies, we determined that one serine phosphorylation site (293) is increased in late 
pregnant mouse hearts, but did not assay two other potential sites (232 and 300). Furthermore, 
other post-translational modifications of PDH, including acylation, was not characterized. 
Acetylation can affect the phosphorylation status and thus activity of PDH (Jing et al., 2013). 
This, along with directly examining the activity of PDH, would be informative to understanding 
the duration and degree of inhibition.  
In order to determine if PDK4 is responsible for the substrate switch we observe in late 
pregnancy, future studies with PDK4-null mice or PDK4 inhibitors at late gestation and ex vivo 
perfusion of 13C-labeled substrates should be conducted. PDK4 knockout mice at baseline have 
normal serum profiles, but after fasting, have reduced serum glucose and increased fatty acid 
levels (Jeoung and Harris, 2008, 2010). Diaphragms from these mice increase in glucose 
utilization and decrease in fat oxidation. However, metabolic flux in hearts have not been 
directly determined. Treatment with PDK4 inhibitors can provide another method to study the 
role of PDK4 in substrate switch. These inhibitors are under consideration as therapeutics for 
many diseases, including diabetes and certain cancers. One commonly used inhibitor is 
dichloroacetate (DCA), which is a pyruvate mimetic. First, we would determine the substrate 
usage state in both PDK4-null mice and wild-type mice in non-pregnancy. We would expect the 
phenotype to be similar to that of the diaphragm, with more glucose than fat usage. Then, null 
mice or wild-type treated with DCA in late pregnancy would be compared to their non-pregnant 
136 
 
controls in Langendorff perfusion studies of 13C-labeled substrates. We hypothesize that mice 
with re-activation of PDH would exhibit a substrate consumption profile comparable to their 
corresponding controls. This would confirm that upregulation of PDK4 is responsible for the 
change in substrate use in late pregnancy.  
One interesting point worth exploring is the state of neonates from PDK4-deleted 
pregnant females. Since glucose is the primary substrate source of the fetus, and the predicted 
serum profile in mice with PDK4 ablation is lower serum glucose but due to usage by the heart, 
less glucose will be shunted to the fetus. Will this result in decreased litter or neonate size? 
Furthermore, how can this affect future offspring health? This has not been reported in published 
literature. 
Many hormones can regulate PDK4, including insulin, glucocorticoids, and thyroid 
hormone (Attia et al., 2010; Connaughton et al., 2010). PPARα and PGC-1α have already been 
well-characterized to directly activate PDK4 gene expression under different stimuli. In the 
heart, no studies have been done to determine the effects of pregnancy-related sex hormones on 
PDK4 expression. One group did find that implantation of progesterone and estrogen slow-
release tablets into ovariectomized rats led to an upregulation of PDK4 in gastrocnemius, 
although slightly more so with estrogen than progesterone (Campbell et al., 2003). 
Bioinformatics characterization of the PDK4 promoter showed an estrogen receptor binding site 
in a distal enhancer region. However, most studies have focused on more proximal regions and 
thus it is unclear what role this site plays in regulating PDK4 expression. Future luciferase 
experiments can illuminate the direct effects of progesterone on the PDK4 promoter activity. It 
would be interesting to investigate if there is a site for progesterone transcriptional control in this 
region.  
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The importance of selecting a good model organism in the study of pregnancy 
In our studies, we included characterizations of rat metabolic phenotypes during 
pregnancy. It has become apparent that rat and mouse physiology differs more drastically than 
we expected. For example, the serum triglyceride and glucose profiles of late pregnancy in 
mouse and rat contrast each other. While mice show a modest 1.4-fold increase, pregnant rats 
increase serum triglycerides by almost 7-fold. Serum glucose is even more prominent. No 
change is observed in mice but a 40% decrease occurs in late pregnant rats.  Furthermore, many 
previously published studies were completed in rats, and we have found that mouse physiology 
do not always match. For example, the increase in PDK4 expression is not supported by previous 
studies in rats (Rimbaud et al., 2009). In addition to this, expression of C/EBPβ is different in 
mice and rat hearts in late pregnancy and postpartum day 1 (Appendix). However, there are 
similarities in substrate switch preferences in all species examined so far. Furthermore, substrate 
transporter localization are both unchanged in rats and mice. Thus, this underscores the 
importance of choosing the correct model to study metabolism during pregnancy and warns 
against making overarching conclusions based on the results of one model.   
 
Limitations 
Langendorff perfusion and metabolic flux studies  
Langendorff perfusion of 13C-labeled substrates in late pregnant mouse hearts 
demonstrated relative decreases in glucose oxidation and increases in fat usage. While this 
system offers immense control to be able to study different conditions, the environment can be 
vastly different from the whole-body system, but recognition of this can facilitate the 
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interpretation of results. The perfusion buffer composition is pivotal to ensuring that the correct 
conditions have been chosen. It is thus important to select perfusates that closely match the 
environment that the heart is used to seeing, however, that is difficult when studying 
physiological adaptations. For example, we chose to use non-pregnant concentrations of 
substrates to perfuse both non-pregnant and late pregnant mouse hearts as a starting point. Our 
perfusion buffer also lacks insulin and uses slightly elevated concentrations of lactate, which 
likely leads to underestimations of total glucose usage in the non-pregnant and late pregnant 
mouse heart. Other hormones, especially those elevated in pregnancy, such as progesterone and 
estrogen, were also not included. Despite these limitations, the intrinsic cardiac changes we 
observe in late pregnant mouse hearts suggests that the effects are not transient nor affected by 
the increased triglyceride environmental of late pregnancy. 
It is also important to clarify parameters of metabolic flux analysis to ensure that the 
conclusions and inferences made from the data are correct. First, flux analysis is often performed 
in systems at steady state, in which metabolic flux and metabolite concentrations are constant, or 
more realistically, at pseudo-steady state, where minimal changes occur. While glycolysis can 
reach saturation in minutes, the TCA cycle often can take hours for true steady state to be 
reached. We found that in 45 minutes of perfusion, an increase in labeled isotopomer species of 
TCA intermediates was detected compared to 25 minutes of perfusion, which indicates that 
steady state was not reached at 25 minutes. Thus, dynamic metabolic flux analysis of non-steady 
state conditions may more realistically show the utilization of different substrates. Furthermore, 
we did not perfuse hearts with 13C-palmitic acid for longer than 30 minutes and so cannot 
conclude if steady state was reached with 13C-palmitic acid. It would be important to establish 
this for proper interpretation of our flux analysis. Secondly, the measurements determined here 
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with 13C-labeling is the relative metabolic rate of substrate utilization and not absolute rates. 
Using radioactively labeled substrates, such as 14C-glucose, followed by detection for 14CO2, on 
the other hand, would provide absolute rates of substrate utilization.   
In addition to exogenous glucose and fat as energy substrates for the heart, other 
endogenous sources, such as stored triglycerides and glycogen exist. Previous studies have found 
that the triglyceride pool in cardiomyocytes can contribute significantly to fat oxidation and that 
exogenous triglycerides can cycle through the triglyceride pool before being oxidized (Banke et 
al., 2010). We did not measure the triglyceride pool in late pregnant and non-pregnant mouse 
hearts, but it is possible that the endogenous pool contributes energy substrates. If the 
triglyceride pool is greater in late pregnant mouse hearts than non-pregnant mouse hearts, then 
the contribution of endogenous triglycerides can affect our analysis. We assume here that 13C-
palmitic acid concentrations is the predominant supply for β-oxidation, but if the triglyceride 
pool in the heart is also a contributor, then our analysis would be underestimating fatty acid 
utilization in late pregnant mouse hearts. In addition, if our measurements were not performed at 
steady state of label incorporation, then the transit time through the triglyceride pool could also 
affect our conclusions. If this is so, then first order kinetics models cannot be used to determine 
metabolic rates and other models such as second order kinetics may be more applicable and 
necessary to properly calculate rates. 
 
Fatty acid uptake  
We observed an increase in fatty acid uptake into late pregnant mouse hearts in the 
luciferase transgenic mice after injection of a free fatty acid (FFA) conjugated to luciferin probe 
(luc-FFA). The luc-FFA probe was a non-esterified, 16 carbon fatty acid designed to mimic 
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physiological conditions and enter through fatty acid transporters (Henkin et al., 2012). Nutrient 
serum analysis revealed an approximately 50% decrease in fatty acid concentrations in late 
pregnancy in mice. Thus, the diminished endogenous pool of FFA can affect the proportion of 
labeled fat in the serum after injection of the probe. On the other hand, blood volume in 
pregnancy is also significantly altered and can increase by 30% by day 17.5 of pregnancy in 
mice (Kulandavelu et al., 2006), which would offset the error introduced by lower endogenous 
FFA levels. To formally test the final effect, measurements of FFA concentrations in serum after 
injection could be made, though we have not performed these studies.  
 
PDK4 induction in late pregnant mouse hearts 
In late pregnant mouse hearts, PDK4 expression is upregulated, as is a similar increase in 
phosphorylated PDH. The phospho-antibody specifically recognizes serine 293 of PDH, which 
corresponds to site 1. PDK family members have varying capacities to phosphorylate the three 
serine sites of PDH, and PDP isoforms similarly have different activities levels towards each site 
(Patel and Korotchkina, 2006). Thus, expression levels of these enzymes can control both the 
rate and duration of activation and inactivation of PDH in different tissues. In our studies, we 
determined only phosphorylation of site 1, and did not assay for site 2, which corresponds to 
serine 300, or site 3 (serine 232). PDK4 can phosphorylate both sites 1 and 2 of PDH, which 
could affect the degree of PDH inhibition. In addition to phosphorylation conditions, the activity 
of PDH can also be directly measured to determine how it may correspond to the level of 
phosphorylation in mouse hearts. These direct assays are planned for the near future.  
A notable species-specific discordance was observed between rats and mice in terms of 
PDK4 upregulation. While we observed an increase in PDK4 expression in late pregnancy in 
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mice, we do not observe a similar induction in rats in late pregnancy, though decreased glucose 
utilization is still present. This suggests that a PDK4-independent mechanism is in effect in rats 
at late pregnancy. A potential explanation is the “Randle cycle” (or “glucose-fatty acid cycle”). 
Elevated fatty acid oxidation results in a rapid increase in the ratios of acetyl CoA/CoA, 
NADH/NAD+ and concentration of citrate, which results in quick changes of decreased PDH 
activity, pyruvate oxidation, and also inhibition of phosphofructokinase 1 and 2 (PFK1, PFK2) in 
the heart. Thus, the drastic increase in serum triglycerides at late pregnancy in rats could shut 
down glycolysis in the absence of PDK4 upregulation. Furthermore, the increase in fatty acids 
could activate transcription factors, such as PPARα or PPARδ, which would upregulate genes 
involved in fatty acid oxidation and uptake, though we did not observe this in mice. It is also 
possible that AMPK is phosphorylated and activated, which would lead to decreases in malonyl 
CoA concentrations and subsequent augmentation of fatty acid oxidation. However, whether or 
not this occurs has not been explored. Abnormal glucose tolerance and increased insulin 
secretion in the insulin resistant state can also dramatically alter substrate usage. In mice fed high 
fat diets for 2 weeks, fatty acid oxidation is increased in absence of changes in PDH activity or 
PDK4 expression (Wright et al., 2009). In those circumstances, impaired GLUT4 translocation is 
potentially responsible for the reduction in glycolysis and increase in fatty acid oxidation, though 
again we did not see this in mice.   
 
Contribution of glycolytic ATP to ion homeostasis 
Decreased glycolytic flux can dramatically affect the function of ion channels located at 
the sarcolemmal and sarcoplasmic membranes. Many glycolytic and glycogenolytic proteins are 
localized at the sarcolemma or the sarcoplasmic reticulum (SR) in order for ion channels at these 
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sites to preferentially use ATP produced from glycolysis. Thus, glycolysis plays an important 
role to ensure that these channels, such as the SR Ca2+ ATPase, ATP-sensitive K+ channel, and 
Na+/K+ ATPase, are functioning at optimal levels and that ion homeostasis is maintained. In late 
pregnancy, we observe a decrease in glucose utilization, suggesting decreased ATP produced by 
glycolysis. How this affects ion channels that rely on this glycolytic ATP has not been 
extensively explored. One previous study found that the α1-subunit of Na+/K+ ATPase was 
decreased by approximately 20% in late pregnant rat hearts, leading to increased concentrations 
of sodium at steady state (Elzwiei et al., 2013). However, whether this is an effect of decreased 
glycolytic flux has not been studied. Furthermore, under stressful conditions, such as in 
ischemia, glycolytic ATP is important to maintain calcium levels by improving the activity of the 
SR Ca2+ ATPase (Aasum et al., 1998; Zima et al., 2006). These studies suggest that potentially 
decreased glycolysis in late pregnancy could modify the activity of ion channels, ion 
homeostasis, and electrophysiological properties in the heart.  
 
Cardiac LPL  
Another key regulatory point in the uptake of fatty acids is the cardiac lipoprotein lipase 
(LPL). LPL is made by parenchymal cells, such as cardiomyocytes, and then transferred to the 
luminal surface of endothelial cells via heparin sulfate proteoglycans (HSPG) and 
glycosylphosphatidylinositol anchored high density lipoprotein binding protein (GPIHBP1), 
where it can then hydrolyze triglycerides to liberate free fatty acids. Mice with cardiac-specific 
deletion of LPL not only have increased plasma triglyceride levels and decreased fatty acid 
content and oxidation, but surprisingly, also have altered gene expression consistent with 
decreased fatty acid uptake and oxidation, such as reduced expression of CPT1, CD36, PDK4, 
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FATP1, and PPARγ (Augustus et al., 2004; Augustus et al., 2006). Furthermore, basal glucose 
uptake and oxidation in LPL-null hearts was significantly upregulated, along with modest 
increases in GLUT4 gene expression. Consistent with this, positron emission tomography (PET) 
studies of human patients with LPL deficiency show elevated glucose uptake (Khan et al., 2011). 
These drastic phenotypes suggest that LPL plays a pivotal role in controlling substrate usage in 
the heart. In our studies, we found no change in expression of cardiac LPL in late pregnancy, but 
have not explored the activity levels of LPL. The increased serum triglyceride concentrations of 
late pregnancy indicates that LPL may be an important factor in fatty acid uptake. Furthermore, 
usage of palmitate or Luc-FFA overlooks the contribution of LPL as FFA can enter the cell 
without the need for LPL, and perhaps measurements with labeled very low density lipoproteins 
(VLDL) will more closely mimic the physiological environment in late pregnancy. Injection of 
VLDL in LPL-deficient mice determined a decrease in the uptake of lipoproteins (Augustus et 
al., 2006). Mice overexpressing LPL in the heart were found to decrease FFA oxidation and 
increase triglyceride oxidation (Yagyu et al., 2003, Pillutla et al., 2005). Thus, future 
experiments will examine the role of LPL in pregnant mouse hearts.  
 
Conclusion 
Profound metabolic reprogramming occurs in pregnancy. However, much still remains to 
be explored in the metabolic changes of the maternal heart during pregnancy. Deeper 
understanding of these regulations could have significant impacts on the pregnancy-related 
cardiac diseases, such as PPCM, preeclamptic heart failure, and others, of which predisposition 
could likely result from aberrant metabolism.   
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Appendix: 
 
An unknown role for C/EBPβ in late pregnant rat hearts  
149 
 
Introduction 
 
During pregnancy, the heart undergoes physiological remodeling that is similar to the 
“eccentric” hypertrophy observed in athletes. This is characterized by wall thickening and 
volume overload (Bamfo et al., 2007). After pregnancy, there is a rapid reversal of cardiac 
hypertrophy. By 12-24 weeks postpartum, systolic function and left ventricular mass have 
returned to normal (Gonzalez et al., 2007). Other changes such as cardiac output and systemic 
resistance have been found to persist for up to a year.  
CCAAT-enhancer-binding protein β (C/EBPβ) is a transcription factor that plays a 
critical role in a number of different biological processes, including adipogenesis, osteoclast 
differentiation, inflammatory responses, and apoptosis induction. In the heart, heterozygous 
deletion of C/EBPβ protects from heart failure when pressure overloaded (Bostrom et al., 2010). 
In exercise models of swimming, cardiac C/EBPβ expression is downregulated (Bostrom et al., 
2010). This decrease has been directly linked to the increased hypertrophy observed in response 
to exercise through the negative regulation of CITED4 by C/EBPβ. Although the role of C/EBPβ 
in exercise induced hypertrophy has been well characterized, it is unclear if this transcription 
factor also plays a role in pregnancy-induced physiological hypertrophy, or potentially 
postpartum reversal of hypertrophy.  
Here we investigate the role of C/EBPβ in cardiac hypertrophy during and immediately 
after pregnancy. We hypothesize that C/EBPβ plays a similar role in pregnancy-induced 
hypertrophy as it does in exercise-induced cardiac hypertrophy. Therefore, we tested if C/EBPβ 
expression is decreased during pregnancy. Furthermore, as cardiac hypertrophy is reversed in the 
postpartum state, we hypothesized that C/EBPβ expression might also increase postpartum to 
play a role in the reversal of cardiac hypertrophy. We also explored the effects of conditioned 
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media from human placental explants of term deliveries on its ability to induce C/EBPβ to 
determine if these effects are mediated through placental secretion of hormones or cytokines. 
One previous study found that C/EBPβ is induced in mid-pregnancy in the heart, but unchanged 
in late gestation and postpartum (Chung et al., 2012b). This suggests that perhaps pregnancy-
induced hypertrophy has a distinct signaling mechanism compared to exercise-induced 
hypertrophy.  
 
Results 
C/EBPβ expression is selectively induced in the hearts of late pregnant and early postpartum 
rats 
Hearts from rats at different stages of gestation, including mid-pregnancy (D12), late 
pregnancy (D20), and postpartum day 1 (PP1) were assayed for C/EBPβ expression. There was 
no change observed in mid-pregnancy, but in late pregnancy, a post-transcriptional induction was  
  
Figure A.1: C/EBPβ is induced in the heart in late pregnancy and postpartum day 1. 
Quantitative, real-time PCR was performed on rat heart tissue at mid-pregnancy (day 12, A), late 
pregnancy (day 20, B), and postpartum day 1 (C). Western blot was also performed in rat hearts at 
same times as the gene expression.  
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Figure A.2: C/EBPβ expression in other tissues of postpartum day 1 rats. Quantitative, 
real-time PCR and western blot was performed on rat heart tissue at postpartum day 1 for 
lung (A and C), kidney (B and D), liver (E and G), and ovary (F and H).    
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observed (Figure A.1E), as protein is strongly induced while no gene expression changes are 
seen (Figure A.1B). Furthermore, there is an induction in both gene and protein expression of 
C/EBPβ at postpartum day 1. However, no change was seen in CITED4 at any time point, a gene 
that is negatively regulated by C/EBPβ (Figure A.1).  
Protein and gene expression of C/EBPβ was determined in lung, kidney, liver, and ovary 
tissues of postpartum day 1 rats. We do not observe significant changes in gene expression 
(Figure A.2A, B, E, and F). Protein expression appears decreased in the kidney (Figure A.1D), 
increased in the ovary (Figure A.2H), while unchanged in the lung and liver (Figure A.2C and 
G). Interestingly, this may also indicate post-transcriptional modifications of C/EBPβ in these 
tissues. In addition, the late pregnant expression profile was determined in the lung, liver, kidney 
and ovaries of rats, and no alterations are seen in C/EBPβ (Figure A.3). A prominent induction of 
CITED4 occurs in the liver in the absence changes in C/EBPβ (Figure A.3B). Western blot was 
not performed on these samples.  
 
Placental conditioned media induces C/EBPβ in cardiomyocytes 
Since C/EBPβ is induced in late pregnancy, we hypothesized that perhaps placental 
secreted factors played a role. Thus, we obtained human placental explants from term deliveries 
and then incubated them in DMEM for 48 hours before treatment on neonatal rat ventricular 
myocytes (NRVMs) for 24 hours. Quantitative, real-time PCR (qRT-PCR) showed drastic 
inductions in C/EBPβ gene and protein (Figure A.4). Other genes downstream of C/EBPβ, such 
as CITED4 and troponin T (TnT), are oppositely altered, while no significant changes were 
observed for genes involved in angiogenesis or metabolism (Figure A.4). Furthermore, we show 
that this induction is not a nutrient deprivation response (Figure A.5A) and is also due to a 
protein in the conditioned media (Figure A.5B) by dilution of conditioned media and treatment  
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Figure A.3: C/EBPβ expression in late pregnancy.  Quantitative, real-time PCR was 
performed on late pregnant rat tissues, including lung (A), liver (B), kidney (C), and ovary 
(D).  
Figure A.4: Induction of C/EBPβ in NRVMs after 24 hours incubation with placental 
conditioned media. NRVMs were incubated with human placental conditioned media for 24 
hours. Then, quantitative, real-time PCR was performed (A) and western blot was carried out 
(B).  
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with trypsin and heating. In addition, placental conditioned media can induce C/EBPβ expression 
in NRVMs by 4 hours of treatment and is sustained by 8 hours (Figure A.6).  
As both heart tissue and isolated NRVMs contain more than one population of cells, we 
explored if C/EBPβ upregulation is a cardiomyocyte-specific effect or if it is mediated through 
non-cardiomyocytes by isolating these two populations in adult rat hearts by Langendorff 
perfusion. Though C/EBPβ is induced in both populations, a much higher upregulation is 
observed in non-cardiomyocytes (Figure A.7). In addition, we obtained placental conditioned 
media from late pregnant rats and observed an induction of C/EBPβ on NRVMs (Figure A.8A). 
Furthermore, both mildly preeclamptic and preeclamptic human placental conditioned media  
Figure A.5: Induction of C/EBPβ in NRVMs is not a nutrient deprivation response 
and is mediated by protein effects. (A) NRVMs were incubated with different 
dilutions of human placental conditioned media for 24 hours. Then, quantitative, real-
time PCR was performed. (B) Human placental conditioned media was either heat 
inactivated (95C, 15min) or treated with trypsin for 1 hour at 37C and then incubated on 
NRVMs for 24 hours. qRT-PCR was then performed.   
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induced C/EBPβ in NRVMs (Figure A.8B, C, and D). Treatment of pregnancy sex hormones, 
including progesterone and estrogen, however, did not alter C/EBPβ expression in NRVMs 
(Figure A.9A). Soluble Flt (sFlt), an anti-angiogenic, soluble VEGFR1 receptor that is elevated 
at late pregnancy, also did not induce C/EBPβ (Figure A.9B).  
The C/EBPβ response, however, is surprisingly not specific to placental conditioned 
media, as treatment of conditioned media from fibroblasts, MS1 cells (endothelial cell line), and 
10T1/2s differentiated to become pericyte-like cells with TGF-β treatment, also induces C/EBPβ 
expression in NRVMs (Figure A.10). In addition, we observe that other cell types incubated with 
placental conditioned media similarly promote C/EBPβ expression (data not shown).  
 
Placental conditioned media induces apoptosis in cardiomyocytes 
To explore the consequences of C/EBPβ upregulation, we performed microarray analysis 
on NRVMs incubated with placental conditioned media for 24 hours. One of the top upregulated 
pathways found was apoptosis, of which C/EBPβ has been well characterized to play a role in.  
Figure A.6: Induction of C/EBPβ occurs at 4 hours and 8 hours of conditioned media 
treatment. NRVMs were incubated with human placental conditioned media for 4 hours (A) and 
8 hours (B). Then, quantitative, real-time PCR was performed.  
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Figure A.7: C/EBPβ is upregulated more strongly in non-cardiomyocytes than 
cardiomyocytes. Adult rat cardiomyocytes and non-cardiomyocytes were isolated from the 
heart via Langendorff perfusion. (A) Adult cardiomyocytes were incubated with human 
placental conditioned media for 24 hours. Then, quantitative, real-time PCR was performed 
and western blot was carried out. (B) Adult non-cardiomyocytes were incubated with human 
placental conditioned media for 24 hours. Then, quantitative, real-time PCR was performed 
and western blot was carried out.  
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Figure A.8: Rat placental and human preeclamptic placental conditioned media 
incubation on NRVM induces C/EBPβ expression. NRVMs were incubated with rat 
placental conditioned media (A) or human preeclampic placental conditioned media (B and 
C) for 24 hours. Then, quantitative, real-time PCR was performed. Western blot was 
conducted on treatment of preeclamptic conditioned media on NRVMs (D).   
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We determined that placental conditioned media does cause apoptosis in NRVMs (Figure A.11), 
although not as much as the positive apoptosis control, doxorubicin.  
To examine if C/EBPβ is responsible for the increase in apoptosis, we treated NRVMs 
with siRNA for C/EBPβ before incubating with placental conditioned media. We found that a 
second dose of siRNA (“boost”) was necessary to overcome the dominant induction by placental 
conditioned media (Figure A.12A). There is surprisingly no change in apoptosis with knock 
down of C/EBPβ (Figure A.12B), suggesting that C/EBPβ is not necessary for apoptosis 
induction by placental conditioned media in NRVMs.  
  
Figure A.9: No effect of sFlt, progesterone, or estrogen on C/EBPβ in NRVMs. NRVMs 
were incubated with progesterone or estrogen (A) or sFlt (B) for 24 hours. Then, quantitative, 
real-time PCR was performed.  
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Figure A.10: C/EBPβ induction is not specific to placental conditioned media. NRVMs were 
incubated fibroblast (A), MS1 (A), and 10T1/2 (with and without treatment of TGFβ, C) 
conditioned media for 24 hours. Then, quantitative, real-time PCR was performed.  
Figure A.11: Placental conditioned media induces cell death in NRVMs. NRVMs were 
incubated with human placental conditioned media for 24 hours or different concentrations of 
doxorubicin (DOX) as control. Then, cell death detection ELISA (Roche) was performed to 
determine apoptosis status of NRVMs.  
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Figure A.12: Placental conditioned media upregulaton of C/EBPβ does not mediate cell 
death. NRVMs were treated with siRNA for C/EBPβ and then incubated with human placental 
conditioned media for 24 hours. During this time a second “boost” of siRNA was added to cells 
to ensure knockdown of protein (A). Then, the cell death ELISA was performed on all samples 
(B).  
Figure A.13: C/EBPβ is not upregulated in mouse timed pregnancy in the heart. Mice 
were set up on timed pregnancies at a barrier (A) and non-barrier (B) facility. RNA was 
isolated from heart tissue and qRT-PCR was performed on the selected genes.  
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In vivo induction of C/EBPβ in the hearts of mice during pregnancy 
In order to continue to explore the effects of C/EBPβ on pregnancy, a shift to mouse 
models was necessary to conduct genetic manipulations in vivo. Thus, we profiled C/EBPβ 
expression levels in mouse timed pregnancy. There is no change in C/EBPβ expression in mouse 
hearts at any point in gestation (Figure A.13). We explored timed pregnancies in both a barrier 
and non-barrier animal facility to eliminate the possibility of environment that is too clean to 
observe the effect, given the known role of C/EBPβ in inflammation.  
 
Discussion 
We observe marked inductions of C/EBPβ in late pregnancy and day 1 postpartum. In 
late pregnancy, this response may result from post-transcriptional modifications. We also do not 
see a negative regulation on CITED4 with increased C/EBPβ expression. Furthermore, we found 
that this phenotype can be mimicked in vitro with treatment of placental conditioned media on 
isolated cardiomyocytes. However, this upregulation is neither specific to placental conditioned 
media nor to NRVMs, as C/EBPβ induction is observed in other cell types with placental 
conditioned media treatment and also with other types of conditioned media on NRVMs. 
Furthermore, we determined that the C/EBPβ response is not necessary for induction of cell 
death observed with treatment of conditioned media. We did not however, test if C/EBPβ is 
sufficient to induce cell death in NRVMs. This can be done by overexpressing C/EBPβ in 
NRVMs and determining the levels of apoptosis compared to control. If so, this would suggest 
that placental conditioned media stimulates multiple pro-apoptotic pathways, and inhibition of 
the C/EBPβ pathway is insufficient to prevent apoptosis.  
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We also carried out timed pregnancy studies in mice, which showed no change in 
C/EBPβ expression at any time in pregnancy. We did not assess C/EBPβ expression levels in 
isolated cardiomyocytes from pregnant mice. However, a previous study found an induction of 
C/EBPβ in mid-pregnancy, though not late pregnancy or postpartum (Chung et al., 2012b). The 
striking increase in C/EBPβ in rat hearts during pregnancy, in addition to its known roles in 
exercise-induced hypertrophy, suggests that C/EBPβ could also be important for pregnancy-
related adaptations in the heart. The lack of CITED4 repression in our experiments, however, 
suggests that perhaps hypertrophy is not the downstream phenotype that is provoked by C/EBPβ. 
It is difficult to perform genetic manipulations in rats, and the disparity between rat and mouse 
physiology in pregnancy made it difficult for us to further explore the role of C/EBPβ in 
pregnancy with genetically manipulated models. We hypothesize that C/EBPβ plays a role in rat 
pregnancy, and perhaps AAV9-mediated delivery of C/EBPβ, which specifically targets the 
heart, during pregnancy could provide an answer on its role.  
 
 
Materials and Methods 
Animal studies. All animal studies were performed according to procedures approved by the 
Institutional Animal Care and Use Committee (IACUC) at Beth Israel Deaconess Medical Center 
(BIDMC). Mice were maintained on a standard rodent chow diet with 12 hours light and dark 
cycles with water and food ad libitum. C57/bl6 mice were purchased from Jackson Laboratories 
(Bar Harbor, Maine). Wild-type, three-month-old female C57/bl6 undergoing estrus were mated 
with wild-type, C57/bl6 breeder males. The presence of a copulatory plug is denoted as day 0 of 
pregnancy. Pregnant females were singly placed in a new cage. Timed pregnancies were carried 
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out to day 11-12 (mid-pregnancy) and day 17-18 (late pregnancy) of gestation. Timed pregnant 
rats (Sprague Dawley) were obtained directly from Charles River.  
Reagents and Materials. Unless otherwise stated, all reagents are from Sigma. The cell death 
ELISA kit was obtained from Roche.  
Gene expression studies. Upon harvesting, mouse tissues were immediately frozen in liquid 
nitrogen. Total RNA was isolated from with the TRIzol (Invitrogen) and chloroform method. 
RNA concentrations were measured with the ThermoScientific NanoDrop spectrophotometer, 1 
µg of RNA was used to synthesize cDNA with the High-Capacity cDNA Reverse Transcription 
kit (Applied Biosystems, CA). Gene expression was assayed with quantitative, real-time PCR 
using SYBR Green dye with specific primer set specially designed and the Bio-rad CFX 384 
Touch Real-Time PCR Detection System. The primers used for mice and rats are listed in Tables 
3.1 and 3.2. 
Western blots. To determine protein expression, frozen mouse tissues were homogenized in the 
Qiagen TissueLyser for 10-15 minutes in RIPA lysis buffer, in the presence of phosphatase and 
protease inhibitors. Protein concentration was determined by the Bradford assay. Approximately 
10 µg of protein were separated by SDS-PAGE, before transferred onto PVDF membrane. The 
primary antibodies were for immunoblot were: vinculin (Cell Signaling) and C/EBPβ (abcam). 
Primary antibodies were incubated overnight at 1:1000. Three TBS-T washes were conducted 
before incubating with secondary antibody at 1:10,000 for 1 hour.  
Conditioned media collection and incubation. Human placental explants were obtained and 
incubated in DMEM for 48 hours. Then, conditioned media was centrifuged at maximum speed 
for 5 minutes to remove tissue debris before storage in -80C. Placental conditioned media was 
incubated on NRVMs for 24 hours.   
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Neonatal cardiomyocyte isolations. Neonatal cardiomyocyte isolations were carried out as 
previously described (Hajjar et al., 1997). Briefly, hearts of 1-2 day old Sprague Dawley 
neonates were excised and ventricles were isolated. Sequential incubations with collagenase type 
II (Worthington) were carried out in a 37oC shaker. Cells were purified from non-
cardiomyocytes via a crude, 1 hour pre-plating step. Cells were then incubated in DMEM, 10% 
HS, 5% FBS, and 1% penicillin-streptomycin (PS).  
Adult cardiomyocyte isolations. Adult mouse hearts were excised and perfused via 
Langendorff perfusion, first with perfusion buffer (137 mM NaCl, 4 mM KCl, 1 mM MgCl2, 10 
mM HEPES, 0.33 mM NaH2PO4, 10mM glucose, 5 mM taurine, and 10 mM BDM), before 
switching to an enzyme buffer with collagenase D (Roche), collagenase B (Roche), and protease 
XIV for 10-15 minutes. Calcium was reloaded with concentrations of 0.06 mM, 0.25 mM, 0.60 
mM, and 1.2 mM. Adult cardiomyocytes were plated on laminin-coated tissue culture plates for 
2 hours in MEM (Invitrogen), 10% calf serum, BDM, 2 mM glutamine, and 2mM ATP before 
switching to labeled media.  
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